Organizers:
Foreword
Power of the past, Force of the future Over the past few years, India has seen unprecedented growth in the Life Sciences sector both as a producer of medicinal products and more recently as one of the world’s most prominent market for healthcare products and services. The growth in the sector has been driven by significant investments and initiatives by both the public and the private sector. Given the multifaceted advantages across the Life Sciences value chain (R&D, Manufacturing and Commercial) supported by emerging regulatory environment, India has finally emerged. Now is the time for both local and global stakeholders to act together and leverage power of India to provide access to quality healthcare products to billions of people around the world. Under this backdrop, the 14th edition of BioAsia organized with the theme “Power of the Past, Force of the Future�, discussed the foundation and initiatives required to achieve the glorious future and brought together experience and expertise of global life sciences industry leaders, policy makers, researchers, innovators and investors to discuss major trends affecting the life sciences sector the ranging from Innovation, Manufacturing, Digital Health and Health IT, Automation in Diagnostics and Health and Access. Witnessing participation of about 1500 delegates representing over 500 organizations and about 400 visitors from 51 countries, the event also attracted many strategic and investment announcements aimed to boost the growth of life sciences industry in the state. Besides, 1200 business partnering meetings were realized during the event. Through the post event report, we intend to bring to you the highlights of BioAsia 2017 including the sessions deliberations, satellite events, participant facts & figures, media coverage, feedbacks &comments, etc, Please do contact us at info@bioasia.in for any additional information. Warm Regards, Team BioAsia
Event Report Book 1
Organizers & Sponsors
2
BioAsia2017
Supporting ORGANIZATIONS & Media Partners
Event Report Book 3
At a Glance
Introduction............................................................ 05 Participant Profile.................................................. 06 Ceremonies & Awards........................................... 07 Keynote Lectures................................................... 15 CEO Conclave....................................................... 25 Conferences.......................................................... 31 Satellite Events...................................................... 71 Media Coverage.................................................... 81 Feedback and Comments..................................... 85
4
BioAsia2017
Introduction
Over the past few years, India has seen unprecedented growth in the Life Sciences sector both as a producer of medicinal products and more recently as one of the world’s most prominent market for healthcare products and services. The growth in the sector has been driven by significant investments and initiatives by both the public and the private sector. Given the multifaceted advantages across the Life Sciences value chain (R&D, Manufacturing and Commercial) supported by emerging regulatory environment, India has finally emerged. Now is the time for both local and global stakeholders to act together and leverage power of India to provide access to quality healthcare products to billions of people around the world. Under this backdrop, the 14th edition of BioAsia organized with the theme “Power of the Past, Force of the Future�, discussed the foundation and initiatives required to achieve the glorious future by initiating better ecosystem and fostering collaborative culture for the Life sciences community.
Event Report Book 5
Participant Profile Over 1200 delegates registered for the 14th edition of BioAsia. In addition around 400 visitors attended the 3 day International biobusiness event. While the state of Illinois (USA) and the state of Selangor (Malaysia) participated as the International Partners, states of Rajasthan and Uttar Pradesh participated as State Partners. Over 51 countries were represented in the event with major delegations from countries like USA, UK, Malaysia, Singapore, Iran, Czech Republic, Germany, Australia, etc. The International Tradeshow of BioAsia 2017 attracted about 100 corporate and startups from across the globe.
BioAsia 2017 Participants during various sessions
6
BioAsia2017
Ceremonies & Awards
Event Report Book 7
CEREMONIES
Inaugural Ceremony
With the theme “Power of the Past, Force of the Future”, BioAsia 2017 kick started its highly anticipated 3-day conference on February 6th, 2017 at Hyderabad International Convention Center in Hyderabad. The event was inaugurated by Shri KT Rama Rao, Hon’ble Minister for Industries & Commerce, IT E&S, MAUD, Government of Telangana on February 6th, 2017 at 6:00 pm. The dignitaries present at the function included: •• Shri E.S.L. Narasimhan, H.E. The Governor, Government of Telangana •• Shri KT Rama Rao, Hon’ble Minister for Industries & Commerce, IT E&S, MAUD, Government of Telangana •• Hon’ble Dato’ Teng Chang Khim, Senior Executive Councillor, Investment, Industry & Commerce, SME and Transportation, State Government of Selangor, Malaysia •• Dr. Soumya Swaminathan, Secretary, Department of Health Research - Ministry of Health and Family Welfare, Government of India, and Director General of Indian Council of Medical Research •• Shri Rajeshwar Tiwari IAS, Principal Secretary - Health, Medical & Family Welfare, Government of Telangana
8
BioAsia2017
CEREMONIES
•• Shri Jayesh Ranjan IAS, Principal Secretary, Industries & Commerce, IT E&C Department, Government of Telangana •• Dr. Paul Stoffels, Worldwide Chairman of Pharma, Chief Scientific Officer, Johnson & Johnson, USA •• Nobel Laureate Prof. Kurt Wuthrich, Scripps Research Institute, USA •• Dr. Ajit Shetty, Chairman, International Advisory Board, BioAsia & Chairman Emeritus, Janssen Pharmaceutica, Belgium •• Padma Shri Dr. D Balasubramanian, Chairman, Telangana State Advisory Committee Life Sciences & Director Emeritus Research, LV Prasad Eye Institute •• Mr. Venkat Narasimha Reddy, Vice Chairman & Managing Director, Telangana State Industrial & Infrastructure Corporation (TSIIC) •• Dr. K. V. Raghavan, Working President, Federation of Asian Biotech Associations & INAE Distinguished Professor, CSIR-Indian Institute of Chemical Technology •• Mr. Madan Mohan Reddy, Chairman, Pharmexcil & Director of Aurobindo Pharma Ltd. •• Mr. Shakthi M Nagappan, Director Lifesciences & Pharma, Government of Telangana & CEO, BioAsia •• Mr. Sudeep Krishna, Partner & Head Lifesciences, Deloitte India Event Report Book 9
CEREMONIES
BioAsia 2017 Inaugural Ceremony in Progress
Mr. Jayesh Ranjan delivered the welcome address highlighting the legacy of BioAsia since 2004 when it was a 7 countries 100 delegates affair to its 14th edition hosting 51 countries with about 2000 delegates. He also mentioned that in 13 years of journey the state of Telangana and the city of Hyderabad has seen more than 5 billion worth of Investment flown in through this forum and more than 200 letters of Intents, bilateral Cooperation agreements have been made and MOU’s have been inked. He also highlighted that India has a tremendous potential of becoming a giant in the world of Biotechnology and the Genome Valley cluster in Hyderabad is contributing significantly in the growth story of India. He also affirmed that the conferences of BioAsia 2017 will unfold discussions upon the cutting edge work which the research labs are taking up and will also showcase the best that India, Telangana and Hyderabad have to offer in terms of Biotechnology Ecosystem. Dr. K. V. Raghavan, in his speech, mentioned how after 13 years of existence BioAsia has acquired a brand name. He also stated that the 14th edition will have over 100 speakers talking on several specialized subjects with about 800 corporates participating in the technical sessions, exhibitions and discussions, more than 100 exhibitors will be taking part in the International Tradeshow and nearly 50 start ups will be showcased. He also informed that the focus area in the case of Scientific Fields will be New Drug Development and Disrupting Healthcare while the sessions on the three days will be looking at the different facets of the innovation, development, manufacturing, digital healthcare, diagnostics, hospital infections etc. Dr. Balasubramanian, in his speech, highlighted that over 35% of the world’s vaccine production for children is made in the city o Hyderabad. He also stated that for the 14th edition of BioAsia the major theme is Innovation which helps to adopt and adapt according to the needs. Dr. Ajit Shetty, in his speech, mentioned that BioAsia has evolved over the past course with the approach of Technology first, business second and to further grow and innovate. He was delighted to note that terrific group of leaders in research, industry, academia, government and public policy along with the other leaders were present in this edition of BioAsia which has the capability of reshaping and strengthening the future of tomorrow. He stated that the 14th edition of BioAsia will be addressing the fast evolving trends relevant to the creation of the opportunity and fostering an Innovation Climate for multi-stakeholders in the space. 10
BioAsia2017
CEREMONIES Hon’ble Minister Dato Chang Khim congratulated the organizers and expressed his delight to be associated with the event. He also mentioned that BioAsia is an important platform for Selangor as it provides them with the insightful information, opinion and expertise that is quite essential for them in building up and strengthening the development of Biotech in Malaysia, especially in the State of Selangor. He also mentioned that their mission in Hyderabad is of seeking collaborations and cooperations that would result in potential successful ventures with India. Dr. Soumya Swaminathan, in her address, expressed how impressed she was with the Telangana Government’s commitment to not only support and promote the research and development but also it’s unparalleled efforts to create a rich environment that is helping Hyderabad in emerging as a hub for innovations and scientific breakthroughs. She also expressed her desire to partner with the Telangana Government and NIN in making the state malnutrition and tuberculosis free. She was also hopeful that Department of Biotechnology, CSIR & ICMR institutes and Pharma companies together can really grow in the region if they share facilities, ideas and quickly move through the translational pipeline. She also urged the doctors to be more involved in the medical research and development and it should start at a level of under graduate education so that they are the mentor for the upcoming generations. Shri KT Rama Rao welcomed all the delegates on behalf of the host state of Telangana. He highlighted how BioAsia emerged as one of the eminent meetings in Asia for the Lifesciences and the Healthcare sectors. He also mentioned that Hyderabad is dominating the vaccine production of India that contributes significantly to the global vaccine production while inching closer to be recognized as a global disease prevention capital. He also acknowledged Genome Valley’s leading position in the lifesciences sector with cutting edge scientific efforts that are unmatched by any other clusters in India. He also affirmed that this year’s theme “Power of the past and Force of the future” will recognize the key areas that will drive the synergies among the key stakeholders. He was also hopeful that BioAsia will become a window to the future of Lifesciences and will deliver the ultimate platform to anticipate the next required shift in perspective, vision and innovation in the area of Lifesciences. Shri E.S.L. Narasimhan, delivered the inaugural address with pressing upon the importance of BioAsia as a forum in the world today in terms of healthcare which has assumed a lot of criticalities. He put forth his views regarding India facing the challenges
Shri E.S.L. Narasimhan, H.E. The Governor, Government of Telangana delivering the inaugural address
Shri. KT Rama Rao, Hon’ble Minister for Industries & Commerce, IT E&S, MAUD, Government of Telangana, delivering the inaugural address Event Report Book 11
CEREMONIES like affordable healthcare and its access to the rural areas and enhancement of research capabilities and its funding prospects. He also proposed that for common ailments today namely diabetes, blood pressure, cancer and eye care some pilot projects in Telangana should be launched so that new solutions can be generated with the lead of corporate hospitals that might help in the early detection of these diseases and the quality of life for the patients can be improved. He also highlighted Telangana Government’s commitment to providing good healthcare to every citizen. Mr. Madan Mohan Reddy proposed the vote of thanks on behalf of BioAsia Organizing Committee to all the dignitaries of event as well as to the media. He also thanked all the business heads and leaders who were present in the ceremony and the FABA members, central and state government officials, who have worked relentlessly to make the event a success.
Shri E.S.L. Narasimhan, H.E. The Governor, Government of Telangana inaugurating BioAsia 2017 International Exhbition in the presence of Shri. KT Rama Rao, Hon’ble Minister for Industries & Commerce, IT E&S, MAUD, Government of Telangana
Welcome Reception The first day concluded with a Welcome Networking Reception at Novotel Lawns attended by delegates from 51 countries.
12
BioAsia2017
AWARDS
Genome Valley Excellence Awards “Genome Valley Excellence Award” was introduced to recognize and honour eminent individuals and organizations for their exceptional contribution to Life Sciences Research & Industry. This year’s Genome Valley Excellence Awards were presented to -
Nobel Laureate Prof. Kurt Wuthrich of Scripps Research Institute, USA, in light of his: •• Exemplary research and pioneering work on the biology, structure and function of proteins and nucleic acids •• Extensive contributions to the field of nuclear magnetic resonance spectroscopy and introducing NMR techniques for macromolecular 3D Shri E.S.L. Narasimhan, H.E. The Governor, structure determination in solution Government of Telangana presenting the Genome Valley Excellence Award to Prof. Kurt Wuthrich in the presence of Shri. KT Rama Rao, Hon’ble Minister for Industries & Commerce, IT E&S, MAUD, Government of Telangana
•• Remarkable Contributions to the structural genomics, proteomics and biomedical research
Dr.
Paul
Stoffels,
Worldwide Chairman - Pharmaceuticals, Executive Vice President, Chief Scientific Officer, Johnson & Johnson, USA in light of his:
•• Remarkable contributions to millions of lives through innovative therapeutic research, particularly HIV and tropical disease research •• Vision and efforts that has helped catalyse innovative science and Shri E.S.L. Narasimhan,H.E. The Governor, technology through collaborative Government of Telangana presenting the Genome Valley Excellence Award to Dr. Paul Stoffels in the global R&D presence of Shri. KT Rama Rao, Hon’ble Minister for Industries & Commerce, IT E&S, MAUD, Government of Telangana
•• Pioneering commitment, as chair of the J&J R&D Management Committee, to discovery and development of treatments for unmet medical needs
Event Report Book 13
AWARDS Prof. Wuthrich in his acceptance speech expressed his delight about the developments in Hyderabad in the area of Biotechnology. He also spoke about the importance of basic research for one to excel in the field of innovation and ensuring that it is carried in the public eye with profitable ways.
Dr. Stoffels in his acceptance speech spoke about his motivation to make a difference in the lives of others and in science. He also said that it is important to start with a vision & a passion and never give up and work towards the invention that will make a difference in the world. He affirmed that science and technology offers unprecedented opportunities but the most important resource is the talent pool that India has, giving it a bright future.
FABA Special Award In order to recognize and honour eminent personalities for their longtime contributions to Biotechnology and Lifesciences sector, Federation of Asian Biotech Associations (FABA) instituted the “FABA Special Award” in BioAsia 2010. This year’s FABA Special Award was presented to -
Dr. Patrick Vallance, President R&D, GlaxoSmithKline, UK in light of his: •• Remarkable contributions in research in the fields of clinical medicine, general internal medicine, cardiovascular medicine and clinical pharmacology •• Extraordinary research work focused on the regulation of vascular tone and blood cell-vessel wall interactions •• Pioneering commitment towards GSK’s Research, Drug Discovery and Open R&D activities
Shri. KT Rama Rao, Hon’ble Minister for Industries & Commerce, IT E&S, MAUD, Government of Telangana presenting FABA Special Award to Dr. Patrick Vallance
14
BioAsia2017
Keynote Lectures
Event Report Book 15
Keynote Lectures Speaker: Dr. Paul Stoffels, Worldwide Chairman of Pharma, Chief Scientific Officer, Johnson & Johnson, USA 9:30 - 10:00 Hrs, February 7th, 2017
Dr. Paul Stoffels spoke about how life sciences industry can succeed by focusing on innovation. He spoke about how Life expectancy in HIV after treatment of almost 10 years of life has gained in which Indian generic industry had a huge role to play. According to him it is just not about treating people but it is about societal welfare. He also spoke about how innovation is about saving and improving lives and it can be measured through years of life, quality of life and value to society. He also talked about how pharmaceutical innovation has delivered significant value to society. It has increased life expectancy through antibiotics, vaccines, cardiovascular treatment, HIV treatment etc. Although it still faces many challenges like Cancer, Alzheimer, Diabetes, cost of development (probability of success) and societal challenges of pricing, value and IP. He also talked about sourcing the best innovation with the collaborative mindset of the scientist through required disease understanding, new platforms, discovery of new targets, biomarkers and early diagnosis. He also spoke about the new technology platforms that J&J is working on internally like Immunology, Cell Therapy, Gene Therapy, Molecular diagnostics for disease interception and guidance. J&J also has innovation centers with equipped people for example incubators like JLabs. According to him there is a slight difference in finding new medicines and developing new medicines where one is very wide and is about finding the best scientists and innovators and the other being very disciplined and knowing exactly what to do to make drugs. For development of innovative therapies there are various approaches like Translational Research, Clinical development, Precision medicine, regulatory pathways and outcome trials. He stated that Indian Life sciences industry is on its way to becoming a global 16
BioAsia2017
Keynote Lectures powerhouse which has an emergent biotechnology industry poised for robust growth, outstanding talent and excellence in the clinical trials, manufacturing and Information Technology strengths. He also advocated that India should have a focus on increasing years of life and the quality of life.
Audience during Dr. Stoffels’s Lecture
Speaker: Nobel Laureate Prof. Kurt Wuthrich, Scripps Research Institute, USA 10:00 - 10:30 Hrs, February 7th, 2017
Event Report Book 17
Keynote Lectures Prof. Kurt Wuthrich spoke about how each successful drug development starts with a discovery or an invention and then goes through many years of development, creating a market and getting the drug to be actually used by the medical community. He spoke about his experiences regarding the introduction of magnetic resonance imaging and how it took two generations of medical doctors to adopt MRI and to use in today’s time where it is more apt to provide the information needed then X- Ray investigations. According to him for the companies the input what usually becomes innovation was basic research that expands to usually a couple of decades (long before one could even imagine that it might be useful for the quality of life for human beings). He also talked about how large public funding is more used towards the tasks that is upon the pharmaceutical industry rather than supporting the basic research that would feed directly into the applied research in large companies 30-50 years from now. He also spoke about his research in NMR in structural biology and its application for studies of large molecules. He also described how his research of NMR structure became innovation as now it has been replicated to nearly 1500 times by the groups all around the world and also around 5000 times by the industry globally.
Audience during Prof. Wuthrich’s Lecture
18
BioAsia2017
Keynote Lectures Speaker: Dr. Vas Narasimhan, Global Head of Drug Development & CMO, Novartis, Switzerland 10:30 - 11:00 Hrs, February 7th, 2017
Dr. Vas Narasimhan spoke about the medical innovation from overall pharmaceutical industry’s perspective. The pharmaceutical and biotech industry around the world invests over 150 billion dollars in research and development. The question always being that is it an efficient use of funds and whether they are receiving the actual returns on the investment (whether to further investment at the current rate on the research). For the pharmaceutical industry now the challenges are of different diseases to conquer namely Cancer, Diabetes, Alzheimer etc. He also spoke about the research areas in which Novartis is involved like reimagining therapeutics, reimaging drug development and further reimagining access. He also spoke about the science of how they develop therapies as he took up a collaboration of Novartis with Google as an example. They were working together for a product called Google lens which was a contact lens bedded with sensors and technology which could accommodate for near and far vision accordingly. This opened up research possibilities of putting other sensors in the contact lens so that the other ailments like blood sugar and blood pressure could also be monitored. He also talked about how there is a change in the manner of data collection and how data mining can be evolved in a way to create better insights to create the next wave of medicines. He also talked about how the industry can solve the access problem. The gap between the access of medicines for the vast majority of the world is too large. He also spoke about Novartis’ access initiative where they are partnering with governments and NGO’s around the world to provide a portfolio of 30 medicines that cost of a dollar per month. He also talked about Novartis’s future in Hyderabad and that it is committed to continuing investment in Hyderabad. Event Report Book 19
Keynote Lectures
Audience during Dr. Narasimhan’s Lecture
Speaker: Mr. Narayana Murthy, Founder, Infosys 9:30 – 10:00 Hrs, February 8th, 2017
Mr. Narayana Murthy spoke about how science and technology can be applied in addressing healthcare challenges for India. India has made tremendous strides in improving health indicators in the last 50 years for example Life expectancy has increased 20
BioAsia2017
Keynote Lectures from 41 years in 1960 to 61 years in 2010. While India’s progress has been steady it lags way behind comparator countries like China and Brazil who have invested considerably more in health. According to him what was concerning was that India was falling behind its neighbors like Sri Lanka and Bangladesh in public health issues. He also talked about how non-communicable diseases have become key contributors to deaths in India as they account for 60% of the deaths and primarily they affect the people in the productive phase of their lives i.e. from 35 to 65 years. They have huge implications in terms of National Productivity. Also the improvement in the health indicators are primarily - progress in our social and environmental conditions like greater access to clean water and better sanitation, growing per capita income, increased use of clean cooking fuels like LPG, impact on improved likelihood due to programs like the rural employment guarantee scheme, advances in science and technology improving our ability to prevent and control diseases, development of new vaccines, wider use of mobile driven health technologies. Such improvement is also due to advances in healthcare innovation and access provision. There are several such examples like Arvind Eyecare Hospitals has produced the much needed treatment to thousands of patients through innovations such as tiered payment and treatment, free of cost to the needy, development of the intraocular lens technologies. Narayana Hrudyalaya led by Dr. Devi Shetty has not only led from the front on the cost effectiveness on the insurance schemes but has also developed low cost cardiac procedures. Trinetra has developed a low cost device for ophthalmic examination and for remote diagnosis. The link with all these three and other innovations is that the scientific knowledge is the driver but major challenges remain however in provision of healthcare in India which are access to people in rural areas, availability of well qualified medical professionals in adequate numbers and lack of financial inclusion resulting in low capacity of purchasing of medical care and medicines for the poor. According to him science and technology can play a key role in diagnosis and management of a disease - mass application of drugs and availability of these drugs on a scale and at an affordable cost. Technology can act as an interface among physicians & patients, physicians & peers and physicians of varying levels of expertise. Substantial evidence indeed exist on diverse role technology can play in several aspects of delivering healthcare, saving cost and improving quality of healthcare. Health management and information systems are the areas which the country lacks and there is a need for a unified health management system - implementation of HMIS as it is called in India. It could prove invaluable for improving data collection, predicting disease burden and local health needs, rapid data collection for outbreaks and for early warning and response. It can also aid in better case management for chronic diseases. HMIS can also aid in teasing the influence of multiple determinants of Health. Big data analysis of large health datasets can help better understand the various environmental, social and behavioral risk factors. This kind of research can influence better policy making across sectors which are otherwise considered outside the preview of health. Technology can also be used as a driver for provision of primary care services as it can strengthen sub centers with technology enabled non physician healthcare providers it can improve physical and IT connectivity between sub centers, primary healthcare centers, community healthcare centers and districts hospitals, it can improve referral and follow up systems to ensure Event Report Book 21
Keynote Lectures high risk cases get priority attention, it can promote integrated care through networks of providers who are not physically accessible at all time. There are several opportunities for science and technologies to be interconnected with health to engage in science to engage in problem solving however solutions need to be connected to ground realities. There is a potential to enable mass application of solutions and provision of care at an affordable cost. He also spoke about the requirements of investment from both the federal and the state government levels in public healthcare for research and development. He also reaffirmed that healthcare is the most important facet in the development of the nation and government and public health sector and medical professionals have a responsibility to help deliver quality healthcare to the people.
Audience during Mr. Murthy’s Lecture
22
BioAsia2017
Keynote Lectures Speaker: Dr. Patrick Vallance, President R&D, GSK, UK 10:00 - 10:30 Hrs, February 8th, 2017
Dr. Patrick Vallance spoke about open innovation. According to him there are 4 big questions essentially while developing a drug- which target to go after, which molecules are to be used to make the drug, how in the clinic can it be demonstrated that there is some effect which looks as it is affecting the human biology in the right way and lastly how the true clinical value of the medicine can be described to patients, prescribers and healthcare system. According to him open innovation can be a process or mechanism to achieve substantial innovation to improve healthcare in a way it is more accessible. He also addressed the question of why open innovation is important, why to do it faster and cheaper, to generate new ideas and approaches, challenge oneself, create an environment in which it is easier to operate because we have societal trust. He also talked about how knowledge base is essential for drug discovery in Human Genetics. The more that knowledge base becomes fragmented and protected, lower is the chance for everybody to invent the medicine. There is a need for structured information regarding human genetics to be readily available for the use in drug discovery and also be open to everybody. Another reason for this is the foundational knowledge that elevates the industry’s ability to develop medicines which can be achieved through wide spread connectivity across biotechnology and academia. He also talked about that the notion that openness is giving away value is not correct. It creates the opportunity to allow stimulation of new companies and allow an ecosystem that flourishes because it has a knowledge base to grow upon. He also talked about importance of a geographical ecosystem which requires academia, biotech, big pharmaceutical companies, tech companies, government funding in the right place along with incentives. Event Report Book 23
Keynote Lectures According to him the advances in the human biology as well as the pace of understanding has never been greater and faster and is leading to a huge generation of data which cannot be handled by individual groups and needs to be integrated across groups. He also said that open innovation is the foundation for allowing a flourishing system but it is not the one that remains perpetually open. Thus there is also a need for the IP of the product which is the value creator. He also affirmed that open innovation is the key part of any successful innovative system and creates many benefits that cannot be predicted in the beginning.
Audience during Dr. Vallance’s Lecture
24
BioAsia2017
CEO Conclave
Event Report Book 25
CEO Conclave
SERVING A BILLION PATIENTS
Time
: 18:30 - 20:00 Hrs
The Role of Indian Life Sciences Industry
Date
: February 07, 2017
Venue : Hall - 6, HICC, Hyderabad
Panelists: •• Mr. KT Rama Rao, Hon’ble Minister for Industries & Commerce, IT E&S, MAUD, Government of Telangana, India •• Dr. Vas Narasimhan, Global Head of Drug Development & CMO, Novartis, Switzerland •• Dr. Patrick Vallance, President R&D, GSK, UK •• Mr. Satish Reddy, Chairman, Dr. Reddy’s Laboratories Ltd., India •• Mr. Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd., India •• Dr. Murtaza Khorakiwala, Managing Director, Wockhardt, India Moderator: Ms. Shereen Bhan, Managing Editor, CNBC-TV18 26
BioAsia2017
CEO Conclave Context: • How do we spur manufacturing, is China model to adopt for India, what could be the approach for value based pricing in the context of emerging markets. President Trump – What will his talk on the bringing down pricing mean to the globe? • What is government’s ask from the industry? • How do we bring down the cost involved in drug discovery and development? • How are companies bracing Trump’s regulations, such as changing how FDA works? • What are the big challenges in servicing a billion new patients and what role does the government have to play? • Beyond flexibility in pricing and no cap on pricing, what other than this that government can do? • What can companies do to be more global? • What is the path forward for the emerging markets like India and what should government do? • Is generosity and collaboration possible in pharma industry? • If we look at the global market “quality with reach” is the motto, but in India 75% of the population are denied access for affordable medicines, even if we have the lowest prices, why and how is this happening? • Do the IPR issues in India exaggerated or they make sense? Mr. KT Rama Rao stated that in a capital and R&D intensive industry, all organizations spend billions of dollars, and we cannot expect new markets/medicines very easily. Government should bring in IT and improve infrastructure and regulations to bring down prices. Government has dual responsibility, support infrastructure for companies and provide drug access to large population that cannot afford. In a country like India we need to strike a balance. Private sector is important and it’s interesting to see how change will be brought without much impact. Industry should start looking and treating (especially emerging market) differently. Hyderabad accounts for 35% of pharma production. The tradeoff between drug discovery and drug delivery to common man needs is to be understood. In pharma world, innovation is associated with R&D and we should be conscious to this idea. Government has to enable infrastructure and it needs to keep innovating. Hyderabad is the only city to provide animal center and a huge pharma university and the government is trying to innovate, incubate in the same space. India does not have advocacy groups like US and hence the ecosystem needs to be more holistic and bring more innovation. Government is coming out with research institute which is bringing together academia and large MNCs and trying to bring out a balance and in a pre-competitive space trying to help with costs and profit. Government provides tax benefits, but it has lost credit in people due to malpractices. Dr. Patrick Vallance talked about balance between access to existing medicines is one priority, and between innovation for the next generation. Special cases such as antibiotics should be made available. Big problems in drug discovery is where to start. Second area: Event Report Book 27
CEO Conclave Big economic change, trial costs need to be dramatically reduced. This will happen when we manage trials better. It is a technical issue and also a regulatory issue. Regulatory disharmonization is a big problem. It is not clear yet what the Trump policies mean but it’s reasonable that we need more manufactures. Government should get stability in pricing. A good mix of academia and biotech research need to be accounted for. Government should also give tax incentives and co –investments. India has a real skillset and strongly emerging data and mathematical approach to biology. A key to collaboration is Open innovation. Companies should not look at secretly developing drugs. Foundational platform should enable invention of drugs. Currently everyone wants to own more of the pie. If you look at generics, every week a new gene model is discovered but most is done in academia and which is why we need more open resources. Tier pricing is the solution to provide affordable healthcare to all and as a company we are aware and looking to attack this problem and companies should be accountable. Dr. Vas Narasimhan spoke about how the pharma industry has not been as modern as others in adopting modern technology such as telemedicine. Big data and analytics need to be used. If industry pursues this forward there will be a cost reduction. The opportunities for harmonization are better now but cannot happen overnight and it will take time. Until we see the actual policies from the government of US, it is difficult to adjust the business. We need strong rules by FDA and Novartis supports science based FDA to help everyone get medicines. The large MNCs need to take a tiered approach and should have tiered pricing. The government should become a part of the ecosystem. This helps build capabilities locally and develop investors locally and creates a more sustainable environment. When industry has a common playground it is helpful for all. Another means of collaboration will be outside of pharma such as with technology. Need
28
BioAsia2017
CEO Conclave to reach villagers is important and companies need to come up with innovative ways for the reach. As data systems improve and tech and pharma collaborate then it is possible the reach is improved. Mr. Satish Reddy talked about how servicing a billion patients is a big challenge and that needs of emerging markets are very different from developed. Government participation is important. We need a holistic approach. Go beyond cities and go to Tier 2 & 3 where healthcare is not up to standard. Focus is become on pricing as the government is not allocating money. And in India the prices are the lowest in the world. And it will be a problem if we look a further reducing the price. It should be multidimensional. When we look at regulatory bodies aboard – funding mechanism is significant and they have regulatory pathways where they provide incentives. Model of balanced ecosystem needs to be created. Companies need to look at global model. Collaborative research needs to be done across globe. In India innovation is new. And India is a very generic based industry and does things in silos and hence collaboration is a must. India exports globally. The manufacturing is world standard but the regulations need to be world standard. We also need to address the issue of skillset from the academia and retaining existing employees. Mr. Glenn Saldanha described how government can help in ease of drug discovery by supporting infrastructure. Collaboration is a must as only one company cannot run everything and it also helps in hedging risk. The argument is at what stage can we collaborate. Collaborations for Glenmark has been in the early stages in the drug discoveries. As time progressed we look at Stage 2 and 3 after drug discovery. It depends on where the company is in the lifecycle and how much risk can it take. For Indian companies we need partnerships and collaborations. There is no difference between global and domestic drug market. The leading Indian companies thrive hard to maintain highest quality Dr. Murtaza Khorakiwala stated that in India, similar to Japan, right now we have many companies that have a global reach and the problem is that government is not looking at utilizing that. Right now the thought process is that government is only looking at pricing. The government needs to take into account that if they want India to become global it has to invest in R&D. A standard is commonly adhered by all in the Indian market. The regulatory framework and FDA compliance is important to develop system and structure to regulate the quality. There has been a significant change in the Indian system and it is helping the manufactures. Recommendations: Ways we can assure to serve 1 billion patients: • Balance innovation with affordability • Reach out to the lowest stratosphere of Indian society as a part of Corporate Social Responsibility • Get the pricing volume right and re-invest in developing countries • Keep investing in break-through innovation, continuous manufacturing, prevention of diseases across the globe (e.g. no smoking, diet, exercise) • Social initiatives (e.g. a program called medical van that serves 25,000 people) Event Report Book 29
Participants during CEO Conclave
CEO Conclave Panelists
30
BioAsia2017
Conferences
Event Report Book 31
Conferences
BioAsia 2017
Session Sponsors
Innovation Conference
February 7, 2017 | HICC, Hyderabad, India.
Disruptive Innovation (Panel Discussion) 11:35 - 12:15 Hrs
Panelists: • Mr. Ganesh Krishnan, Founder, Portea Medical, India • Mr. Dheeraj Batra, Co-founder and VP Business Development, Arogya Finance • Mr. Abhishek Anand, Principal, Healthcare & Lifesciences, Korn Ferry • Mr. Kaustubh Bhatnagar, Business Lead, Shruti – Innovation Programme, Medtronic India Moderator: Mr. Sudeep Krishna, Senior Director and Head Lifesciences, Monitor Deloitte Deloitte Consulting Context: Talks around innovation should not be restricted to only innovation in products, the horizon needs to be expanded. Innovation means providing the same product/service of better quality at a lower cost. E.g. Japanese car market, Sony, generics (disrupting the branded medicines), shift from cardiothoracic surgery to angioplasty. 32
BioAsia2017
innovation Conference Session Proceedings: Mr. Ganesh Krishnan spoke about how Industries change for different reasons like in a crisis (Lehman Brothers) or competitive dynamics. He then briefed the audience on how Portea Medical came about. India had great pharma brands, hospitals, and latest equipment but outside of the hospitals there was a vacuum. So the thought was if solutions like data mining, hyper local last mile, on demand delivery can be implemented. Portea started with two services but now it has nine services, which are all consumer driven. The three things driving this in the developing nations are: • A huge need for the services and the regulatory environment supporting this • A gap in the global healthcare facilities – primary healthcare, rise in demand for wellness, nutrition etc., and if all these facilities can be provided at home. Offering an entire lifecycle from birth to end – doctor on call, dietary advice, and giving vaccinations at home. • Can information be provided to the customers (information discovery)? Smartphones, wearables allow viewing patient compliance, etc. and helps disrupt the healthcare landscape. He also stated that 10 years back, all the disruption came from C2C companies whereas in the coming 10 years, it will come from companies that partners with regulatory bodies and include all stakeholders in the process. However, one always faces different challenges such as building credibility, operational challenges etc. Since credibility is always questioned by the big players in the market, you have to do is refine, reposition the product. One needs to explain why an individual or a startup should perform/provide the services and why hospitals shouldn’t. Another challenge includes building trust with the patients because they are used to going to hospitals. When patients go to hospitals, the power is in the doctor/hospital whereas when the clinician goes home, the power shifts largely – from the doctor/medicines to the family. Mr. Dheeraj Batra talked about customer centricity. According to him it is the heart of innovation. If customers are not kept in mind then there is very little success. An example is when a low cost insurance product was developed for the financially challenged, it didn’t work because that’s not what customers wanted. If they have extra money then they will spend on more food or clothes or school and not insurance. Large companies assume that innovation has to be low cost, however, it’s not always about the low cost factor. Eg – Nano didn’t do well in the market because of social/reputation reasons. So, the question here is - is low cost really a differentiating point? Mr. Kaustubh Bhatnagar spoke about how if one tries to align innovation to a large organizations’ working, then the amount of funding it needs is put on a back burner (if one follows a traditional approach). Traditionally, the approach has been to develop a product, go to the market and sell it. Keeping customer centricity in mind, the program Shruti was designed differently. Access and lack of information are two major problems so the program was developed in a way that low cost portable devices could be taken to the patient at their doorstep, maintaining customer as the main point. R&D is central to the innovation endeavor. One has to address the customer needs even in R&D. Also, R&D has to be sourced locally and it has to be around developing products that are portable and smart so the doctor can see the results at his office. Event Report Book 33
innovation Conference Mr. Abhishek Anand talked about the Lipitor’s story and his experience with the brand. Its patent expiration date was Nov 30, 2011 and it had sales worth $31bn globally. The two things Lipitor enjoyed was brand equity, and exclusivity. While Pfizer had good innovation but they didn’t know how to sell it. So, the norm that the product should not be promoted two years before expiration was challenged. Patients who wanted a brand were paying out of their pockets for the drug. Managing change is a repetitive process where you have to explain the value process at every step to all stakeholders. Mr. Sudeep Krishna summarized the session by stating that there needs to be a close collaboration within the ecosystem, it should be a win-win for all stakeholders and should be consumer oriented (traditional approach to disruption is one sided). Low cost needs to be accompanied by initiatives around awareness and access. Established players can disrupt the market and themselves. Recommendations: • Innovation is providing the same product /service of better quality at a lower cost • At the same time, low cost is not always a differentiating factor, it might need to be accompanied by initiatives around lack of information and access • Traditional approach is a one-sided approach to innovation; customer centricity is a must when it comes to innovation • A close collaboration needs to be established within the ecosystem, where all stakeholders are involved in the process equally leading to a win-win situation for all • Large companies can disrupt the market themselves; when there is a disruption in a value chain, it needs to be communicated at every step to all stakeholders.
Audience during Session
34
BioAsia2017
innovation Conference Enabling Innovation (Panel Discussion) 12:15 - 13:30 Hrs
Opening Remarks: Dr. Renu Swarup, MD, BIRAC, Dept. of Biotechnology, Govt. of India Chairman: Padma Shri Mr. BVR Mohan Reddy, Founder & Chairman, Cyient, India Panelists: • Dr. Murtaza Khorakiwala, Managing Director, Wockhardt, India • Mr. Ranjit Shahani, Chairman & MD, Novartis, India • Prof. Pramod P. Wangikar, Professor in Charge, Wadhwani Research Center for Bioengineering, IIT Bombay • Ms. Amiee Aloi, Deputy Vice President, International Advocacy, PhRMA, USA • Dr. Malathi Lakhshmikumaran, Director & Practice Head - Life Sciences Group, Lakshmikumaran & Sridharan Attorneys, India Moderator: Padma Shri Dr. D Balasubramanian, Distinguished Scientist & Director Emeritus Research, LV Prasad Eye Institute Context: Exploring ‘Enabling Innovation’ from different perspectives including the industry, academia, foreign parties, and the government. Session Proceedings: Dr. Renu Swarup spoke about how India needs to move on to enabling innovation from an academic research. Focus for Department of Biotechnology is to change the innovation model - bring in enablers, connect the industry & academia and strengthen Event Report Book 35
innovation Conference that connection further. It’s happening through various government and industry based projects. Further, in India, IP needs to be managed which will build a level of trust and bring together industry and academia. BIRAC is now supporting tech startups also which help collaboration between the two. Now, they are also working towards an acceleration ecosystem to see if the industries and academic institutes can collaborate. There is a cluster mapping for the entire South region and parameters to encourage collaboration. The key issue identified is lack of an institutional mechanism. A pipeline of young innovators are being created, the government is providing them enablers, once they have some innovation ready, the government needs to provide a platform for that as well. An example of bridging the gap in communication of what the industry does/thinks of the academia and vice-versa is that most IITs now are connected through research programs. Mr. BVR Mohan Reddy talked about how global competitiveness is increasing, and technology is available for enabling innovation. As a result, there are multiple advantages like product design has decreased, and the ability to address larger markets has increased. There is a need is to manage IP and open R&D – what can be disclosed, where can it be disclosed, and how much can be disclosed. There are failures and successes in this space. Boeing 787 would be considered a failure. Some success stories are: • GE has platforms called Firstbuild – used for consumer electronics with suppliers, customers, education instructions, etc. • NASA – promote a math algorithm for their future manned missions • Cyient – GTF defines primarily a gear box built into it now costs $900 mn instead of $1.4 bn for R&D Another ingredient is that it is a continuous process – one has to take risks, status quo is questioned, patience is a must, work and build as a team, and create trust - build a social safety net. The future of Open Innovation lies in complex innovation. For instance, in case of an ECG equipment, not only domain expertise is required but also expertise in wearables, sensors, Bluetooth knowledge, data and predictive analytics is needed. Innovation ecosystem needs to be developed, and with that frugal innovation is also a must. A good example of frugal innovation is Managalyaan. There are multiple forums, platforms given the digital technology is there now, where the industry and academia can meet and bridge the communication gap. It is definitely not at its best and has the potential to be better. There are still some hesitations about Open Innovation but with globalization, they will loosen up. Prof. Pramod Wangikar described the role of a university in Open Innovation. University’s contribution is to apply knowledge to real life business problems. Companies hire talent, or offer internships, invest in research at universities, invest in a startup, develop a virtual lab, and sponsor a project. There are 99 companies that have been incubated at IIT Bombay, which are mainly pharma companies. Wadhwani Research Center and IIT Bombay collaboration has been a very successful one. There are a large number of ideas that come up in the industry so the faculty members are keen on more support from the industry, especially since the government support is reducing. What academia needs from industry is idea validation, mass manufacturing, market needs assessment, joint field trails and help in scaling up. 36
BioAsia2017
innovation Conference Ms. Amiee Aloi spoke about how Indian government has undertaken many initiatives like Make in India, Startups campaign, and Innovation campaign. When we talk to industry leaders, their concerns are around policies, investments are made based on the transparency in the economy and policies play a great role. The four categories that are important for enabling open Innovation are: • Requirement of a scientific and expert regulatory environment • Research and an academic community • HealthCare system that values innovation • Industrial effort, public and private partnerships New treatments should have higher quality, lower side effects, and lower morbidity. Take the example of treatment of cancer – New treatments would include adopting our own bodies’ immune cells to target cancer cells so we can move away from chemotherapy. One has to be careful in how much the startup reveals while getting investments, however, there is a robust partnership between US and India with respect to sharing of knowledge, scientists, etc. Dr. Murtaza Khorakiwala talked about how every organization has a vision and a strategy - key drivers, focuses on trends and competencies and what it needs to get there. Innovation fits there somewhere – no one model exists that fits all. Every company decides what a relevant model to realize their goals is. One of the main drivers of growth and success is innovation. 2-3 things that have happened in the last 20-30 years like – • First, cost of innovation is increasing, R&D productivity is increasing so finding more cost effective methods • Second, rate of change in technology, sciences – material or biological, communication sciences is on the rise. This has led to diversity in skills, capabilities, and specialization. Different kinds of innovation models exist even during the entire process of discovery of molecules at different phases. Another model is that of a collaborative one where two parties come together and co-develop molecules in any phase. It leverages the strength of the individual partners, reduces the cost in bringing it to the market place, at the same time also share the risk and resources, and the rewards. Collaboration can happen at a basic level – academia/industry, or in the drug development cycle. • Thirdly, the government plays an important role where there are high pressing social needs such as TB, malaria which invites academia and industry together. Major disruptors for the future include 3D printing, automation in manufacturing & sales, regenerative medicines, and telecom industry Dr. Malathi Lakshmikumaran spoke about closed and open kinds of innovation. Closed innovation business models are where all R&D happens within the institution, it creates the IP, and get profits from within. Whereas with open innovation, the research is global – could take place in a startup or a university; depending on business needs, it could be out-licensing or in-licensing technologies. Open innovation leads to efficiency, and effectiveness. A good example in the medical device area is that of the Stanford/ India bio design model, which has an interdisciplinary approach. Open Innovation has increased due to venture capital and contract research. Another good model is the IIT Event Report Book 37
innovation Conference Delhi – Pfizer CSR model. There are pitfalls in this area such as the lack of a strong IP regime and licensing, Biodiversity Act, etc. Mr. Ranjit Shahani described how mix of closed & open innovation is required. The percentage of the two will change in the future; risks and rewards need to be shared. Before companies open up externally they need to open up internally. The benefits of Open Innovation are – Cost reduction, improvement in productivity and acceleration of time to market. Recommendations: • The benefits of Open Innovation are – Cost reduction, improvement in productivity and acceleration of time to market. • All stakeholders are very important for enabling Open Innovation, including a strong scientific and expert regulatory environment, a research and academic community, healthcare space which values innovation, as well as the industry where there are public and private partnerships • There needs to be a close collaboration between the industry and academia to enable innovation. The trust between the two is lacking, which needs to be built. A strong institutional mechanism will play a big role in connecting the academia and industry, and strengthening it further • Complex Innovation is the future and frugality is a must • Universities have research capabilities and talent to offer to the industry. They require more support from the industry in terms of idea validations, mass manufacturing, and scaling up • Every organization has different perspectives and innovation models to realize their goals, however, it is important to look outside of the company especially with the changes happening in the industry in terms of technology, R&D, and the collaboration between academia and the industry.
Audience Interaction during Session
38
BioAsia2017
innovation Conference Patent protection and value of Innovation and R&D (Panel Discussion) 14:30 – 15:45 Hrs
Panelists: • Dr. Anil Koul, Director, CSIR-Institute of Microbial Technology, India • Mr. Sanjiv Navangul, Managing Director, Janssen India • Ms. Kanchana TK, Director General, OPPI • Ms. Krishna Sharma, Managing Partner, Corporate Law Group Moderator: Ms. Anju Ghangurde, Deputy Asia Editor, Scrip Intelligence (Informa) Context: The fundamental question is do patents actually foster innovation? Historically, US has said that patents foster innovation, that is, a combination of startups and patents directly result into jobs and innovation. There is an increasing need for public R&D spend in institutions to develop affordable drugs especially for neglected diseases like TB, malaria. There is a requirement of more collaboration in India. The academia/industry collaboration is very weak, corporate minilabs and bio clusters are missing. What is the reason for the lack of connect - Is it because of the scientific talent or the companies don’t want to do collaborate. Should India stick to frugal innovation? Is it time to revisit on ‘Section 3D’? Session Proceedings: Dr. Anil Koul spoke about how having a secure patent regime is very important. According to him not only filling the IP but also commercializing it is important. There Event Report Book 39
innovation Conference is a need to have a robust regulatory body in the ecosystem. Problem is credit sharing. Take into account that 10-12 years are required to develop a drug, embrace each other, and collaborate. For instance, take a look at the budget for CSIR – 4000 crore for R&D is set aside but how do we galvanize the R&D? It is a complicated process because the drug development process is complex. There is a disconnect between the industrial R&D/generic R&D and public sector. A relationship needs to be established between the two - public and private, they need to collaborate and can’t work in silos. We can’t be frugal in all innovations. For big pharma, the concept of open Innovation is not new. In India, there are many bio incubators but they haven’t been populated. What is seen in terms of India being the hub of generics, there is a need to reach out to Indian labs like CSIR, universities who want to deliver. Indian academia lacks mission led projects, the outreach hasn’t happened now. Mr. Sanjiv Navangul talked about how Innovation is not dependent on anything. Why is IP attached to it? Patenting is not about commercialization, it is about respecting people for what they do. There are trust issues in this atmosphere, all stakeholders think that other stakeholders have a hidden agenda, industry wants to make profits, government is lagging behind, and in academia people have no practical experience. To develop an ecosystem, we need to build infrastructure like Telangana government has done, invest in people and work together to build something special and trust will build on its own. When it comes to the patent regime – India is still an evolving system. Price index and affordability can’t be used as a patent infringement case. On a different note, India can demonstrate expertise in innovations like data which maybe will help us save man days, maybe capture the patients early on etc. IT solutions, data mining & insights are key drivers for innovation and India could be a pioneer in this. Ms. Krishna Sharma spoke about patenting and innovation. According to her Innovation = research (30% of the budget) + development (70% of the budget). Patents is a reward system, it gives the holder of the patent the ability to keep the third party away. The expectation companies have is that those who file for patents will have the legal environment available. Section 3D should never have been included in the law. Applications from India shouldn’t be allowed due to Section 3D, however, companies are still applying it. 3D is the additional patent criteria. The law is not TRIPS compliant. We are steaming local innovation by having 3D. Article 39.9 gives the exclusivity on the data that you get from the drug development process which is absent in India (Trips +), we also don’t have the linkage and give approvals to people who do not have patents. In the current scenario of WTO, Brexit, the Trump regime, it would be very difficult to see the patent term but there would be enough reason to increase the patent life. Ms. Kanchana TK spoke about how India is a good example of how policy is improving the innovation environment. A more refined approach, and course correction is required. It is important to realize that educating people is important (from law schools - DIPP is doing roadshows etc., to judiciary, and business ecosystem - investments in R&D). A lot more needs to be done from the govt., the budget hardly says anything about R&D. Take the example of Apple – it focuses a lot on innovation, and very little on incremental innovation (iPhone is an incremental innovation). If any innovation is better in efficacy, safety, and compliance for the end user, it should be considered differently. Insulin analogs improved something significantly which will be incremental innovation. With 40
BioAsia2017
innovation Conference the evolving space since there are no special courts for patent infringement case. It is not simple to take decisions on these cases. Recommendations: • Having a secure patent regime is extremely important in fostering innovation. There is more to patents than just commercialization, it is about respecting the work of the innovator • The Indian IPR policy is still work in progress and much needs to be done about it. Government needs to put in more effort to improve the IP environment • There is an increasing need for spending on the public R&D in drugs for neglected diseases like malaria, TB. The public sector, in order to galvanize the R&D budget, should connect with the industry. There is an increasing need for the two – the industry and public sector R&D to connect • An improved IPR regime could mean more foreign R&D investments/hubs and more science jobs for Young India
Audience during Session
Event Report Book 41
innovation Conference Design Led Thinking: Shaping the future of healthcare (Panel Discussion) 16:15 – 17:30 Hrs
Chairman: Padma Shri Dr. D Balasubramanian, Distinguished Scientist & Director Emeritus Research, LV Prasad Eye Institute Panelists: • Mr. Parameswaran Venkataraman, VP & Studio 5B Lead, Innovation and Design Centre, Dr. Reddy’s Laboratories • Mr. Guenter Jagschies, Senior Director, GE Healthcare Life Sciences, Germany • Mr. Manoj Kothari, Managing Director-Turian Labs, Co-founder-Onio Design Pvt. Ltd • Dr. Arup Mazumdar, Design Thinking Evangelist, Researcher, Clinical Business School Faculty, Founding Fuel Moderator: Mr. Harsh Kapoor, Director, Deloitte’s Innovation Group (Doblin) Context: It is vital to understand what is Design led Thinking and its principles and frameworks and how the Healthcare space is embracing Design Led Thinking. Session Proceedings: Dr. D Balasubramanian spoke about how the talk should be about thinking based design, and not design based thinking giving an example of LV Prasad Eye Institute. There are about 1.3 billion people. Out of which 1.8% are legally blind and more than 70% live in rural areas. 50% of these rural people are education deprived. Social issues play a great role like availability, affordability, accessibility, and acceptability – a 42
BioAsia2017
innovation Conference gender imbalance. In a survey of 80 million people taken in Andhra Pradesh, 60% of the blindness can be treated. Challenges are the large numbers, quality, and equity in care, sustainable eye care team, community participation, linkage with Healthcare. The strategy is to expand and reach down to town and villages. Mr. Parameswaran Venkataraman described design thinking with an example of Cambodia. In Cambodia, there is a big iron deficiency. The solution was making iron in the shape of a fish (Fish is symbolic in their culture). They asked them to put this iron fish in the food they cook so that way there was iron being added in the food and problem was solved. Another example is that of a tablet packaging at Dr. Reddy’s, which lets the patient read the back even if they have consumed the tablets. Design thinking starts with the customer – its desirability, technical feasibility and then business viability. Another thing that needs to be understood is whether the problem of unmet needs for the patients is being solved or not. For instance, how do you design the right solution for something like if one has to take the med half an hour before a meal? This is more of a behavioral problem. Design Thinking can be applied to help and improve the lifestyle of the patient. Lifestyle is a behavioral problem, no matter how much medicine one has, lifestyle changes have to be made. Mr. Manoj Kothari spoke about how design thinking is not only restricted to the physical aspect but also the mental/intellectual and emotional aspect of the patient. For accessing healthcare, the psychology of the person should be taken care of. With the help of psychology, we can cure a lot of diseases like the effect of placebo. The mental medicine concept has been around for a while, now holistic help is coming in. This is where homeopathy and allopathy should come together. How best do we build empathy in design in healthcare? Design Thinking has been carved out of many other fields like psychology, sociology, philosophy, etc. Now there are scientific methods to empathize like observe people, having a conversation with the patient. Dr. Arup Mazumdar described how with the help of an exercise, the concept of behavioral approach is shown. Exercise is - that I have INR 2,000 to give away. There are two options • Sure gain of INR 1,000 (majority voted for this option in a show of hands) • 50% chance of a gain of INR 2,000 or a 50% chance to gain nothing. Then the proposition changes (basically reframed from a gain to a loss situation) • Sure loss of INR 1,000 • 50% chance to lose 2000 or 50% chance to lose nothing (majority voted for this option in a show of hands) Second concept – how does problem framing work? Why is there a predisposition towards non-verbal design? To capture emotions, if one shares an idea, it becomes an insight, insight in practice is invention and if it does well for you it will be innovation. Design led thinking is about looking at possible futures, experimenting, and reinventing. The idea must appeal to lizard brain, emotional brain, and the super brain – the cortex, the behavioral brain. Design Thinking is intuitive; a synthesis of a lot of cultural and social angles (a lot of analysis behind it). One has to be comfortable with the unknown. Like, there should be a model where the doctor stays with the patient and observes the lifestyle. Event Report Book 43
innovation Conference Mr. Guenter Jagschies talked about two problems to be solved – the company’s and the customer’s. Biggest problem is how to be successful in making a particular thing that everyone does. You need to add something to these molecules to get to the market. E.g., Genova in Pune. How do you get the cure to cities like Hyderabad, and Mumbai? Another problem is to solve cost since India has so much poverty so how to most efficiently develop and manufacture and invent to. One has to leave behind the traditional ways in the pharma industry like talk to each other about ideas. The company helps develop meds for the customers, but design it in such a way that the customers can buy it. To lead to a breakthrough in drug development, Design Thinking requires everyone - companies/ institutions for it to work together and solve a problem, how can we better share how to do business. Recommendations: • Design Thinking is customer centric, it starts with the customer –desirability, technical feasibility and then business viability. It not only addresses the physical aspect but also the mental/emotional aspect in people • A behavioral approach needs to be taken to solve the problem, for instance – bringing about changes in the lifestyle. A hit and trial method is the best way to solve for the problem between the two extremes – knowledge and analytical view • Sometimes, it is not the medicine that makes the difference in the patient’s healthcare, it could also be made via various other way such as an app monitoring the patient’s vitals • Majority believed that design led thinking is expected to have a significant impact in driving innovation in life sciences industry and it is believed that both large sized drug manufacturers and mid-sized firms will adopt design led thinking in Healthcare Industry.
Audience participation in the Session
44
BioAsia2017
Conferences
BioAsia 2017
Automation in DIagnostics
Conference Sponsors
Conference
.5,<$
70
,QQRYDWH $IIRUGDEOH +HDOWKFDUH
February 7, 2017 | HICC, Hyderabad, India.
Context: Despite impressive advances in the field of diagnostics and vaccination, world is facing the threat of emerging diseases and as India continues to be a leading market for diagnostics, laboratories are experiencing challenges, such as increased testing volume, shortage of qualified and skilled labour, slow results and turn around time, changing testing demands, inefficient processes and under-performing equipments that need to be addressed through concerted efforts. BioAsia 2017 Diagnostics and Automation CME brought together PoC users, regulators, diagnostic companies and suppliers to discuss future of rapid testing, automation challenges, quality control, legislation, diagnostics, and the future of PoCT going forward. Introductory Remarks 11:35 - 11:45 Hrs Dr. Shanthi Naidu, Head of Department, Laboratory Medicine, Care Hospitals delivered the welcome address for the conference highlighting how we have moved a long way in laboratories and diagnostics sector and that because of NABL, which has streamlined many processes due to which all the labs being big or small are trying to comprehend and fulfill the rules and regulations. Plenary Address: Automation in Diagnostics is it the END? 11:45 â&#x20AC;&#x201C; 12:45 Hrs Dr. Sujay Prasad, Consultant Pathologist, Anand Diagnostic Laboratory, Bengaluru shared his experience over last three decades as a user of Automation. He talked about the common views among people regarding automation like decreased human intervention, increased need for software & hardware technology, thereby increasing the ability to manage a larger volume of work, also if implemented effectively it will decrease errors thus saving labor and cost. According to him, understanding the need for Automation is important as the needs of the labs might be different from one another as the processes are viewed differently and there needs to be sync between the actual needs and the perception of the need. He also stated that automation is not an end but is a means to patient care, profitability, research or growth and evaluation (which are the different aspects of the end) and all of them are brought together by the capability of the organization. Capability has three Event Report Book 45
Automation in diagnostics Conference essential aspects - resource, processes, priority and results. The need for automation depends upon the means that a lab currently has, processes in place to utilize those resources and the priority of the lab management. He also mentioned about how through automation they are trying to minimize noise and increase the signal by using Data Science thereby improving quality and also image documentation minimized record keeping. He also spoke about the challenges that his laboratory faced with total lab automation which were the barcodes, alias interface, sorting and routing rules and locating samples on the track. According to him the future of Automation in labs lies in Machine learning and deep learning along with work flow improvements, data analytics and predictive analytics. Invited Talk: Pearls and Pitfalls in Automation in Antimicrobial susceptibility Testing 12:45 – 13:15 Hrs Dr. Ranganathan Iyer, Senior Consultant, Microbiology and Infectious Diseases, Global Hospitals, spoke about how Automation has adapted itself in microbiology in the field of blood cultures and also in continuous monitoring systems (blood and bone marrow cultures and sterile body fluids where automation has been put to use for microbiological diagnosis of an infectious disease. Automation is being used in laboratories to hasten the process of handling samples with identification of organisms; also it reduces time and labor intensiveness as compared to conventional method offering a rapid diagnosis in certain cases. According to him Microbiology does not lend itself very easily to automation as compared to many other branches of lab medicine. He also talked about the advantages of the automated systems which are improved reproducibility, saves cost (only if inoculant standardization for organisms is perfect) and provides quick results (limited to gram negative organisms). Company Presentation 13:15 – 13:30 Hrs Mrs. Anuradha Moturi, Kriya Medical Technologies, Chennai, manufacture phlebotomy tubes and preanalyticals used in labs and diagnostics. Kriya Medical Technologies has been founded to bridge the gap between affordability and accessibility and also to provide medical solutions in the emerging market like India. She spoke about “using technology to identify and solve gaps in practical context”. There are multiple diagnostic devices especially in a blood chemistry environment like biomarkers, electro-mechanical technology and electrochemical technology with point of care devices and radiography also the cutting edge nanotechnology. Kriya’s portfolio spans devices that use chemistry, electro chemical technology for point of care test as well as is working with a start up in collaboration with WHO to develop nanotechnology to diagnose both infectious disease and life style diseases. She also spoke about the key drivers that have driven the industry to advance 46
BioAsia2017
Automation in diagnostics Conference beyond basic technologies and devices for diagnostics-faster detection (technologies to improve accuracy and also to reduce the reaction time) and efficiency increment by reducing errors. According to her while improvements to basic science will result in incremental outcomes also to find solutions and solving practical problems affordability and accessibility by creating a complete ecosystem with connected devices and artificial enabled technologies with achieving speed and accuracy. Panel Discussion: Existing ecosystem & way forward of Automation in Government, Semi-Government, Private, Corporate, Standalone, PHCs, and Rural Health Centers & Diagnostic Services 14:30 – 15:45 Hrs
Chairman and Moderator: Dr. Shanthi Naidu, Head of Department, Laboratory Medicine, Care Hospitals Panelists: • Dr. Animesh Bardoloi, Head of the Department, Dept of Laboratory Medicine, Narayana Super Specialty Hospital, Guwahati • Dr. Rachel Jacob, Dept. of Biochemistry, Nizam’s Institute of Medical Sciences, Hyderabad • Dr. Ranganathan Iyer, Senior Consultant Microbiology and Infectious Diseases, Global Hospitals • Dr. Mukesh Agrawal, Vice President-CR, Vimta Labs Ltd. • Dr. Jasbinder Kaur, Department of Biochemistry, Government Medical College & Hospital, Chandigarh Session Proceedings: Dr. Shanthi Naidu started the discussion with the question to all panelists that is automation a necessity and at what level should it be incorporated in the Laboratory. Dr. Ranganathan Iyer shared his experience of his lab where they have built up services for automation for coagulation profile, hematology, and biochemistry. He also suggested that the labs and departments should come together and meet to discuss the common features of the samples came in at a certain point of time. Dr. Shanthi Naidu raised the Event Report Book 47
Automation in diagnostics Conference need for the identification for centers of excellence to channelize the resources in certain areas like infertility where the demands of the society are high. Dr. Iyer added that there is a need of change in mind-set and attitude among professionals so that a combined effort channelized with the government can be made in this direction. Dr. Rachel Jacob discussed as Nizam’s Institute of Medical Sciences is a semi government set up they have to raise their own funds thus they have more tenacity to get the diagnostic devices as required. The lab at NIMS is a tailored lab catering to meet the ends of multiple specialties at the hospital. She also spoke about the teaching program where the interaction between clinicians and physicians should be promoted. She also mentioned that NIMS follows a tender process for the department specifications and that for government set-up it is not easy to adapt automation in pre-analytical area. Dr. Animesh Bordoloi stated that Narayana Super Specialty Hospital has automation in different streams namely the brain analytics, in analytical factors and in post analytics. All these are linked by the corporate office and they provide the privileges to all the centers. Dr. Naidu also mentioned in a comprehensive lab an interpretative report should be given to the clinician and in today’s times the reports should not be isolated. Dr. Mukesh Agrawal mentioned that Vimta Labs is multidisciplinary system so they face a challenge of giving correct reports to the patients. Each and every section of their lab evolved according to the necessity of the user and they are trying to use automation to have control systems built-in and have module systems available in a controlled fashion. He also mentioned while choosing automation, instrument or a process they seek to find out pros and cons, outcome of the particular process if implemented, how the performance of the laboratory is leveraged(& in what way) Ms. Jabinder Kaur spoke about the difficulty in the adoption of integration report like person’s comfort level, time-table clashes etc. She also spoke from her experience where her lab has flourished with the use of automation due to reduction in work load and errors.
Audience during Session
Recommendations: • Recognition should be given to the colleges and faculties where there is high-quality infrastructure and well qualified faculty so that the future technicians are at par with the technology trends • A center of excellence is required which can be deployed in every part of the 48
BioAsia2017
Automation in diagnostics Conference country state and city wise where the vendors can certify the excellence based on the number of calls made, least number of breakdowns and optimal maintenance of the instrument. • A set of primary health centers should be affiliated to a government medical college department so that the professionals are reportable to that department and that the monitoring is administered. Invited Talk: Defining competencies in automation for laboratory professionals 16:15 - 17:00 Hrs Dr. Pragna Rao, Associate Dean, Professor, Department of Biochemistry, MAHE Manipal, discussed about the requirements for the personal competency assessment which are namely direct observation (of routine patient test and instrument maintenance), calibration and function checks, monitoring recording & reporting of test results, QC records, preventive maintenance records and assessment of Problem solving skills. She stressed upon the fact that young technicians are lacking sufficient trainings in terms of pre-analytics, post-analytics, point-of-care testing, LIS and HIS. She also mentioned that the competencies in automation are essential for all the lab technicians to learn phlebotomy skills, use of LIS and middleware. She also spoke about the needs of a clerkship program for technicians with labs with a training period of 6 months which will improve their lab management skills. Also she suggested that if certain guidelines are set with the technicians under this program, there will be advancement in their performance and they will be able to develop tacit knowledge by working alongside the laboratory professional/expert. She also pressed upon the mode of lectures to be more case& scenario based with narrative and reflective practices to build problem solving skills among technicians. Invited Talk: Use of Immunoassays in diverse industries in India 17:00 – 17:30 Hrs D r. J a y a n t B h a n u s h a l i , F o u n d e r, A m a r Immunodiagnostics, spoke about the use of Immunoassays in different fields ranging from food, feed, poultry, aquaculture, seed testing, GMO’s etc. Immunoassays from medical perspective is used in blood grouping, infection detection, hormone detection, cancer detection, toxicology etc and from industry perspective it is used in animal feed industry (as a growth promoter), meat industry(meat identification), GMO’s, dairy industry, plant tissue culture, Vaccine industry, Pharmaceutical industry, poultry industry, seed industry, Aquaculture, food allergens. In conclusion he also mentioned that while antibiotics are used for human diseases, 80% of it is used as a growth promoter in animals, also more PCR tests are done in agriculture to select a better variety of plants. Event Report Book 49
Conferences
BioAsia 2017
Manufacturing Conference
February 8, 2017 | HICC, Hyderabad, India.
Make in India – The power of manufacturing clusters (Panel Discussion) 10:35 - 11:45 Hrs
Panelists: • Hon’ble Dato’ Teng Chang Khim, Senior Executive Councillor, Investment, Industry & Commerce, SME and Transportation, State Government of Selangor, Malaysia • Mr. Sudhanshu Pandey IAS, Joint Secretary, Department of Commerce, Government of India • Mr. Manni Kantipudi, CEO, GVK Biosciences, India • Mr. Srini Srinivasan, Managing Director, Hospira • Mr. Mathew Szuhaj, Managing Director, Deloitte • Dr. Satakarni Makkapati, President Biologics, Aurobindo Pharma Moderator: Ms. Archana Shukla, Assistant Editor, Pharmaceuticals, CNBC-TV18 Context: • Can we borrow from examples of the world, in manufacturing clusters? Is it not fair to believe that each country is different and needs are different. What is it that India can do in terms of cluster formation? What applies to Singapore and other global markets cannot apply to India as it is a big country? • Should India look at therapeutic clusters to increase manufacturing base? 50
BioAsia2017
Manufacturing Conference • From the perspective of make in India for the life sciences sector, how much progress has India done in terms of brining VC to this space • Only 5 to 6% promised in investor summits in each state actually materialize in the real time. From government perspective, why is it that there is a lag • How can the huge skillset gap be met, between the skillset a job seeks and skillset fresh graduates posses • Should government be more up to date and proactive to account new trends such as 3D printing and keep pace with it and invest in such trends. Session Proceedings: Mr. Mathew Szuhaj spoke about how in biologics there are distinct clusters. Scientific curiosity can get people to join clusters. Singapore faces a lot of competition for talent. Victim of their own success, managerial positions are difficult to find as they are in demand. In India, clusters result from historical coincidence. Clusters can be planted and can grow. In India there are already clusters but in spaces that are very nimble. If the path of growing clusters needs to be done, then competition amongst peers cannot exist. Mr. Manni Kantipudi talked about how the infrastructure can be set up in India, but the biggest challenge is people and regulatory quality standards. If there is a manufacturing cluster, we do not have the right people. Infrastructure setting up is the easier part in the ecosystem of change. Dr. Sattakarni Makkapati explained how clusters in Europe have developed around research institutes, when such a university based cluster is commercial, it is different. In India, considering Hyderabad, there are very good research institutes and most research is funded by companies and there are incubators. But there is not funding or money by the government until they reach a commercialization stage. Overall there is no risk money that is invested in the therapeutic area in India. Singapore model, the closest that India can adopt, is a good model and to replicate there has to be a government push in the pharma space. Mr. Sudhanshu Pandey spoke about how each country has found its own model. India is evolving and its biggest strength is pool of scientific man power. A lot of the man power has moved out of India. There needs to be push from the bottom of the pyramid to drive the clusters. Man power exits in India but with no right skillset. The life sciences and health care skill council are working together with the industry and have started working aggressively to have a skilled man power around the cluster. The pace in India is slow due to socio political dynamics but it is steadily moving in positive direction. The Make in India for life sciences has been moderately successful, but the bigger MNCs are trying to move into the space steadily and the growth in global and in India is going at a steady pace . Even on the vaccine side, there has been a steady growth in India. If India were to invest about 5 billion dollars in skilling and incubation then the biotech industry can become a 100 billion industry. Government has created clusters of chemical and life sciences labs. And it will take time for these clusters to get functional and for the labs to grow and eventually it will match up to the industry through collaborations. Mr. Srini Srinivasan talked about how long the ease of doing business is going to take and how fast is it going to get done? At the optional level there is a long complexity. Event Report Book 51
Manufacturing Conference Recommendations: • The industry will continue to grow organically. Investing, integrating and selling more is key • Take the academia to industry, build standards and quality culture • Jobs will follow money. As industrialists, the motto should be to be successful so as to help people get employed • Stakeholders should not work in silos • Government’s mindset is changing in terms of looking at industry to support it by giving the right working environment
Audience interaction during Session
Manufacturing - Impact of regulators (Q&A Session) 12:15 - 13:30 Hrs
52
BioAsia2017
Manufacturing Conference Panelists: • Mr. David Churchward, Expert GMDP Inspector, Medicines & Healthcare Products Regulatory Agency (MHRA), UK • Ms. Mahima Datla, Managing Director, Biological E. Ltd. • Dr. Satyanarayana Chava, CEO, Laurus Labs • Mr. Parrish M. Galliher, Chief Technology Officer, Upstream, GE Healthcare Life Sciences, USA • Mr. Sandeep Oke, CPO - Vice President Global Procurement, Piramal Enterprises Limited Moderator: Mr. Vikas Dandekar, Chief Editor - News, CNBC TV18 Context: • How can pharmaceutical companies gear for better quality standards and avoid errors in the sensitive space especially, transcription errors • How can business plans be made based on regulatory bodies • How can a balance between profitability and quality be maintained and is automation could be the key to many problems, how do we bring it in? • Are there any differences in the quality standards of manufacturing between global and domestic markets Session Proceedings: Mr. David Churchward stated that more forums are necessary for regulatory engagements and for industry and technology companies to meet. GMPs are fit for purpose and drive the harmonization agenda. Success of the activity depends on engagement with industry. Contract manufacturers are in difficult situation, they are expected to produce a product with highest quality without minimum information. There is a difficult balance, as they need to strike balance between costumers and regulators. Most useful CMOs are the ones who interact best with their clients/customers. Dr. Satyanarayana Chava spoke about how interaction between various stakeholders is obvious and necessary in the current scenario. Product specification can be changed based on client. Many times the operating systems are required to change but this is a challenge as trend in saying NO to such change requests is gaining popularity. There needs to be a cultural shift. Mr. Sandeep Oke stated that advantage with big customers is that they are willing to invest in quality standards and have the financials to collaborate with players across the supply chain and such a partnership is good. India should not follow automation as seen in global space as it has a huge man power to be able to help. Mr. Parrish M. Galliher described how for clients across the biotech sector, responses need to be very malleable for the QMS systems. It is an opportunity to help companies advance the systems of the customer companies. Companies should also look at parameters such as problematic conditions on the equipment. It is a judgment call between business and operations to choose between profitability and quality. Important Event Report Book 53
Manufacturing Conference parameters are: how to invest in quality in a smart manner and how well you understand the product. If the critical quality products are understood then it can be tracked down to quality checks and implementation systems. There should be no over implementations. Indian companies are taking a grip on the situation and are taking these things seriously better than ever. Ms. Mahima Datla described how automation can be very challenging in biological process, as you require a certain amount of human discretion. Quality and safety is the onus of every member in the eco system. Industry needs to make significant investments in quality. Recommendations: • Communication, investing in quality & data integrity as well as the need for one standard procedures are the way to combat quality concerns • Most useful CMOs are the ones who interact best with their clients/customers • For clients across the biotech sector, responses need to be very malleable for the QMS systems. It is an opportunity to help companies advance the systems of the customers companies • Companies should also look at parameters such as problematic conditions on the equipment.
Audience interaction during Session
54
BioAsia2017
Manufacturing Conference GST – Thumbs up or down for life sciences supply chain (Panel Discussion) 14:30 - 15:45 Hrs
Panelists: • Mr. Sunil Jain, Commissioner of Customs, Central excise and Service Tax for Hyderabad II Commissionerate • Mr. A. Vaidheesh, VP, South Asia & MD India, GSK • Mr. P S Easwaran, Partner, Deloitte Moderator: Mr. MS Mani, Senior Director, Deloitte Context: • Government should provide an update in terms of where things stand with respect to GST • The reduction in indirect taxes is not passed to the consumer and is taken by the other players in the eco system. How would GST effect controlled pricing • Explain industry preparedness for GST. How is government preparing its officials to put GST in effect including trainings to employees and others Session Proceedings: Mr. Sunil Jain spoke about how 9 meetings of the GST council have taken place and most processes have been finalized. The GST law has been finalized. The mechanism involved in anti – profit section cannot be implemented in a simple manner and involves complexity. Between pre and post GST, major change is the switch between the taxes. GST is also being projected as a source of revenue which will boost in the times to come. Medicine sector neither Government nor any other player would like the rates to Event Report Book 55
Manufacturing Conference go up and secondly the medicines which need strong regulations also need the prices to go down. Private Health care service would come under the tax net. The training is being conducted in full swing and many seminars and workshops are being conducted for trade industry. Mr. A. Vaidheesh talked about how GST is a part and parcel of every board room meeting in the last year as it is a positive disruptor. If the case is that the medicine needs to be passed on to the nation and citizen, is the need for tax justified. In pharma industry large portion of business is in price control. It is questionable if the industry will be allowed to take price increase till the tax bracket. We should thank the government to make it work and the industry is preparing for it well. Mr. P S Easwaran stated that areas in adopting the GST are not being implemented because people think that there is time available based on the target July month and lack of leadership. Recommendations: â&#x20AC;˘ GST is being projected as a source of revenue which will boost in the times to come â&#x20AC;˘ In the medicine sector, neither Government nor any other player would like the rates to go up; medicines which need strong regulations also need the prices to go down â&#x20AC;˘ GST was a topic of discussion in every board room meeting in the last year as it is a positive disruptor. Most people argue if the case is that the medicines need to be passed on to the nation and citizens, is the need for tax justified?
Audience interaction during Session
56
BioAsia2017
Conferences
BioAsia 2017
Digital Health & Healthcare IT Conference
Session Sponsors
February 8, 2017 | HICC, Hyderabad, India.
Funding the next wave of digital healthcare startups (Panel Discussion) 10:35 - 11:45 Hrs
Panelists: • Mr. Anand Govindaluri, Founder & CEO, GOVIN Holdings, Singapore • Mr. Bobba Venkatadri, General Partner, Ventureast • Mr. Srinivas Kollipara, COO, T-Hub Hyderabad • Mr. Sandeep Singh, Principal at Eight Roads Ventures • Ms. Manjulika Otto, Senior Manager, National Research Development Corporation (NRDC) Moderator: Mr. Sudeep Krishna, Senior Director and Head Lifesciences, Monitor Deloitte - Deloitte Consulting Context: It has become vital to discuss the potential that digitization of healthcare service delivery offers in India, drawing upon similar success stories and initiatives of the developed markets while understanding current stakeholder unmet needs especially for manufactures, physicians and customers and also recognize the prospective role that investor can play in bringing together various players in the ecosystem (industry, academia etc.) to deliver end-to-end solutions. Event Report Book 57
Digital Health & Healthcare IT Conference Session Proceedings: Mr. Sudeep Krishna spoke about role that digital innovation can play in improving healthcare delivery and addressing affordability concerns. According to him, funding is available for all the players in the ecosystem for experimentation and work around the innovative ideas. Mr. Bobba Venkatadri talked about how Digital health financing has increased by 400% globally in last 4 years to reach $7.6bn in 2016. In first half of 2016, 40% of these investments were at seed level for early-stage, high-potential, and growth companies. Telemedicine, wearables and mHealth apps are top three funded categories of Health IT technologies since 2010. Globally, number of exits from digital health startups has increased by 200% from 2012 to reach at 156 in 2016, reflecting opportunities and achievements of healthcare start-ups. Consequently, confidence of global investors has increased considerably in health startups. Digital health startups give tremendous opportunity for building global brands. Investment prospects in Indian healthcare startups are relatively bleak. In 2015, digital health startups received funding of $247mn for 25 deals, which dropped significantly in 2016 to $90mn for 28 deals. However, growing healthcare market in India provides a huge opportunity for budding digital startups provided they focus on the following: • Be precise on what problem are you solving for the patient • Are you giving patients the best in class service? • Building great teams and strategic partnerships Mr. Anand Govindaluri described four important parameters which play major role in evaluation of a startup team which are: • Value proposition: It is important to understand and evaluate value proposition of start-ups. Currently, most of the startups are focusing on app based products. Therefore, differentiation of value and experience being delivered to customer is important to recognize. • Management: Founders of the start-ups should have clear goal in their mind. Leaders should be passionate about their idea to enthusiastically spread it across the organization • Go-to market strategy: Startups should have strong action plan for approaching the customers by overcoming the challenges faced from competition • Contribution to the society: New idea should have a potential to fulfill unmet need of the society Mr. Sandeep Singh spoke about challenges that healthcare industry is facing and role this situation can play in deciding the composition of startup team. In India, Healthcare has emerged as an area of interest only in last 10 years. Therefore, technology adoption propensity is very different in India in comparison with developed markets; Indicated by low adoption of technology enabled services among doctors. Digital healthcare startups should be realistic about tendency to adopt of technology by various stakeholders in the ecosystem. Hence, it is an advantage to have the entrepreneur who is part of ecosystem and understands situations from stakeholder’s perspective. Moreover, if the team is blended with open minds than it would be even better. 58
BioAsia2017
Digital Health & Healthcare IT Conference Mr. Srinivas Kollipara spoke about how healthcare should focus on finding the right problem and exploring the depth of the situation before directly jumping on to the solutions. It has been observed that IT professionals, building core structure of the digital solution, mostly work without looking at the market side of the problem. There are considerable innovations happening in the healthcare space, however it should be combined with right market experience. Therefore, if startups focus on selecting and targeting the right market, there is a tremendous opportunity for innovation in healthcare. Ms. Manjulika Otto described how it is expected that investors should care less about revenue generation and profitability and focus more on problems, which startups are trying to solve. Some start-ups take time in shaping up and investor should focus more on long term vision, which can be served by patent-centric approach. There is shortage of mentors for guiding and sharing industry experiences with digital healthcare startups How digitalization has changed physician’s life? Physicians in the audience shared their experiences and spoke about role of digitalization in engaging patients. Innovation of new interactive apps has helped doctors in delivering coordinated care. However, with increasing information at patients’ end, it creates environment of anxiety for simple issues, which otherwise could have been managed effectively. Recommendations: • Globally, funding for digital healthcare startups is on rise. However, India lies on early spectrum of growth where increasing opportunities in healthcare is expected to draw more funding • To secure funding, healthcare startup should have clear value propositions, strong management, sound go-to market strategy and impactful contribution to the society • Startups team should have set of open minds, who can figure out right problems. Members from healthcare system is add-on, however not must to have. • Digital healthcare start-ups need strong mentors who can share industry experience and guide them in right direction • Investors are expected to focus more on long term vision of startups rather than profitability and business revenues at an early stage.
Audience during Session Event Report Book 59
Digital Health & Healthcare IT Conference Digital Health: Will startups drive the growth? (Panel Discussion) 12:15 – 13:30 Hrs
Panelists: • Mr. Jayesh Ranjan, IAS, Secretary to Govt. of Telangana, IT, E&C, Industries & Commerce Department • Ms. Deepanwita Chattopadhyay, Chairman & CEO, IKP Knowledge Park • Mr. Aniruddha Rajurkar, Vice President, India Commercial Head, Dr. Reddy’s Laboratories • Mr. Radhesh Kanumury, Country Lead, Global Entrepreneur Program, IBM India Pvt Ltd. • Mr. Vipin Pathak, Co-Founder & CEO, Care24 • Mr. Apoorva Patni, Director, Currae Healthcare - Patni Enterprise • Dr. Varun Gupta, Vice President, Medical Affairs, 1mg Moderator: Mr. Srinivas Kollipara, COO, T-hub Hyderabad Context: Digital Health has become a key talk-point and it is important to discuss how startups can play a bigger role in providing better care & delivery and also understand the opportunities for startups in healthcare market to unleash their capabilities. Session Proceedings: Ms. Deepanwita Chattopadhyay spoke about what Digital Health is and that it includes web applications, mobile apps, wearables, managed services, Electronic Health Record, devices that read vitals/scans which improve the health and well-being of people. 60
BioAsia2017
Digital Health & Healthcare IT Conference Mr. Vipin Pathak spoke about how there are various ways that proper healthcare can reach the masses, like policies need to be put in place, accessibility needs to be increased (at a faster pace and a lower cost), and the challenge around the lack of not having enough doctors and health workers needs to be taken care of. It is important for startups to pick up something that established players find difficult to do. There is a lack of doctors but no lack of nurses/pharmacists so there is an increased tendency to work on domains that are more than just delivering the medicine. Mr. Jayesh Ranjan talked about how technology enabled solutions are welcomed for curative or preventive healthcare. Telangana Government has optimally used technology to find solutions like when the medicine is getting over, checking availability of doctor, campaigns, and set up digital kiosks for TB .The government is supportive of new ideas. All partners are excited about new innovations in digital space, however, there is concern about liability. There is a need to address the ownership problem for it to succeed. Dr. Varun Gupta spoke about how Government is always supportive for new ideas. He also mentioned about the biggest challenge that 1 MG faced - changing the mindset of physicians, since they carry lot of baggage. It requires people with different background and open mind set to think about these problems differently and come up with solutions. Mr. Radhesh Kanumury described how Startups are expected judiciously to utilize healthcare data already available in the market. By leveraging big data analytics and cognitive analytics, start-ups can avail more opportunities. In India, doctors in Manipal Hospital have started using these solutions to gauge problems in oncology from symptoms. NeuroEquilibrium is another example leveraging on relevant data to develop tools for curing vertigo problem. There are startups, which have already started focusing on this direction to cater data requirement of doctors, physicians and hospitals. Mr. Apoorva Patni talked about how per capita spend on healthcare is relatively less in India as compared to the developed countries. We need more doctors, nurses in the country. To meet demands of the market in low budget environment, we really need accessibility through digital mode. Infrastructure in digital space is really growing fast specially with arrival of Reliance Jio. Startups can leverage them to reach out to rural population. People need healthcare and sources are improving to provide these services. Therefore, emerging players can play a bigger role in connecting the demand and supply through digital mode for providing access to healthcare. Recommendations: • Accessibility of quality healthcare can be improved significantly through digital mode in low budget environment • To achieve success, it is important for entrepreneurs to pick up something different for their startups which established players find difficult to do • There is abundant healthcare data available in the market. Startups should leverage capabilities of big data analytics and cognitive analytics to generate more opportunities • Increasing innovation in healthcare demands additional responsibility from stakeholders involved in the ecosystem to bring credibility among customers Event Report Book 61
Digital Health & Healthcare IT Conference
Audience interaction during Session
How technology enabled care is transforming India (Panel Discussion) 14:30 - 15:45 Hrs
Panelists: • Dr. Guru N Reddy, Founder, Chairman & MD, Continental Hospitals, India • Dr. Kumara Sanjaya, Head Clinical Specialists, Philips Innovation Campus • Mr. Anubhav Asthana, Director, Deloitte Consulting • Dr. Harish Iyer, Advisor, Bill & Melinda Gates Foundation • Mr. Syam Adusumilli, VP, IT, UnitedHealth Group • Dr. Swati Subodh, Cofounder & Director, Healthcare Innovations 62
BioAsia2017
Digital Health & Healthcare IT Conference • Dr. Manish Pant, Senior National Programme Manager, Health System Strengthening, UN Development Programme Moderator: Dr. Anthony Vipin Das, LV Prasad Eye Institute Context: • Discuss the evolving technology scenario in India with respect to healthcare and how technology is helping in providing better care & delivery? • Understand various challenges that we face while digitalization and lessons that we can learn from developed markets Session Proceedings: Dr. Guru N Reddy spoke about how traditionally, data for physicians was available from various departments in form of hardcopy reports. He drew comparisons with digital era by stating that doctors can now access data through centralized repository and if required analysis can also be performed on these data sets. However, due to multiple responsibilities, doctors mostly resist adoption of new technology. Various well established hospitals tried to bring sudden change in technology across department and faced lot of resistance from doctors. On the contrary, Continental Hospitals systematically introduces the new technologies in hospital, giving sufficient time and space for gradual adoption of technology. Patients are the second most important category of stakeholders expected to get benefited from digital technology. They can stay in continuous touch with their doctors leading to reduction in rate of medication errors. Medical education is also expected to improve drastically with advent of digital technologies. Data gathered through various digital innovations can help researchers in making meaningful predictions. However, it is critical that data should be cleaned before any synthesis is made out of data pool. Dr. Swati Subodh described how technology is only an enabler for providing better access to healthcare. However, it cannot replace human interface between doctors and patients. Skilled people would always be required to operate this technology. Another pressing issue with innovation and new technology is that it has been developed in ‘silos’. It is time to integrate them for providing better access of healthcare. There should be a proper strategy in place to integrate hospitals for finding solutions for noncommunicable disease. Dr. Kumara Sanjaya talked about how technology mostly provides clinical decision support, but does not offer entire decision making. To bring the changes in physicians’ hesitance for using technology, they need to be trained systematically to develop familiarity with systems. New technologies being implemented these days are not cheap. It becomes even more important for us to design technology domestically so that it could be available at economical price. Many Indian healthcare players are already offering technology at cheaper prices. For technology to make an impact in healthcare ecosystem it should be readily accepted, which would only be possible if it is has competitive prices. Mr. Syam Adusumilli described how frugal innovation can be defined as process of reducing the complexity and cost of good and its production. Developing countries are Event Report Book 63
Digital Health & Healthcare IT Conference driving frugal innovation by disrupting the markets in several ways. Low-cost, specialty hospital chains like Aravind Eye Care and Narayana Hrudayalaya have brought down the cost of certain medical procedures significantly. The Indian conglomerate Tata Group and the American healthcare giant GE Healthcare have also developed affordable products targeted at the lowest-income segments in India. Dr. Manish Pant spoke about role of digitalization in improving supply side efficiency of healthcare delivery models. He discussed the example of Electronic Vaccine Intelligence Network (eVIN), which is augmenting vaccination coverage in rural India. They have been training people in rural India on smart phone applications. Accountability has been increased with introduction of digitalization. However, innovation is not sufficient, it should be scalable which requires skilled people and innovative processes. It was suggested that if rural parts of India would be connected through Adhaar card, people can be tracked for compliance of vaccines and other medicines. Recommendations: • Digitalization in healthcare is benefitting all the stakeholders of the ecosystem, however process of introduction of technology should be gradual to prevent resistance in adoption • Technology so far has been developed in silos. It is important to learn from failures of developed worlds and focus on integrating the development of innovation for providing better access to healthcare • It is becoming important to design technology domestically so that it could be made available at economical prices for mass consumption. • Technology is expected to play significant role in improving supply side efficiency of healthcare delivery and understanding the diseases burden during clinical studies
Audience during Session
64
BioAsia2017
Conferences
BioAsia 2017
Health & Access Conference
Conference Co-Organizer
Conference Sponsor
February 8, 2017 | HICC, Hyderabad, India.
Plenary Address: Quality Healthcare Management for Predictable Outcomes 10:35 â&#x20AC;&#x201C;11:00 Hrs Prof. Ramon Z Shaban, President, ACIPC, Australia spoke about the notion of predictability in quality health outcomes. According to him the use of antimicrobials has compromised its value and also it has been exacerbated the inappropriate use in humans and animals. He also stressed that the appropriate use requires a broad span of knowledge of microbiology, infectious diseases and clinical pharmacology. He also said that for the future of infection prevention and control, there must be a formal designation of the prevention and control of communicable diseases, the spread of infections and AMR for societal, political, health and research priorities for both government and NGOâ&#x20AC;&#x2122;s. Opening Remarks 11:00 -11:15 Hrs Dr. Ranga Reddy Burri, President - IFCAI talked about that if HAI and antimicrobial resistance is not controlled in India, it will lose around 5% of its GDP according to the study commissioned by UK Government. There is a large need to tackle AMR which is now a global problem. The solution to this problem is the rational use which can come through education and sensitization of the people who are involved with the treatment of various infections in healthcare sector. Talk: Burden and Implications of Healthcare Associated Infections 11:15 -11:45 Hrs Dr. Palepu B Gopal, Senior Consultant & Head, Critical Care Medicine, Continental Hospitals spoke about the impact of the healthcare associated infections like prolonged hospital stay, long term disability, additional financial burden to the patient, massive financial burden
Event Report Book 65
Health & ACCESS Conference to the healthcare community, increased expenditure on the third party, increased morbidity and mortality. He also talked about the factors that were responsible for the rise of resistance in India which are use of antibiotics for live stock, release of antibiotics to wastewater by manufacturer, lack of sanitation, waste water from hospitals released into rivers, overprescribing or unregulated use of antibiotics and unaffordable drug prices.
Talk: Surveillance Methodologies and its importance in capturing Infection Control Indicators 12:15-12:45 Hrs Dr. Samiksha Singh, Associate Professor, Indian Institue of Public Health spoke about hospital acquired infections and cross infections. She talked about the common hospital acquired infections across India namely Ventilator associated pneumonia, central venous catheter associated urinary tract infections. She also stressed about the importance of surveillance for HAI owing to factors like antibiotic resistant organisms and vulnerable increasing population and also it will reduce the burden of HAIâ&#x20AC;&#x2122;s and associated cost
Dr. Meghana V. Aruru, Associate Professor, Indian Institue of Public Health talked about what risk is as well as its management process which is overall determination of goals, risk quantification measures and possible hazards followed by methods to reevaluate control risk. She also spoke about the risk evaluation tools which are probabilistic risk assessment, Failure modes and effects analysis and Fault tree analysis. She also mentioned that risk control parameters reduce frequency of the event happening like decreasing consequences, duplicating assets, changing the source, implementing standard procedure, engineering controls, training and preparedness.
Talk : Medical Education First - for better Healthcare in India 12:45-13:05 Hrs Dr. S Vijay Mohan, Professor, Department of Internal medicine, Deccan College of Medical Sciences, Hyderabad talked about better opportunities and medical education facilities in India to help build or stronger healthcare eco system.
66
BioAsia2017
Health & ACCESS Conference Talk: Importance of Training and Education for Compliance with IPC Essentials 13:05–13:30 Hrs Dr. Mustafa Afzal, Gen. Secretary, IFCAI talked about behavior motivation theories as they are a key determinant of infection control alongside knowledge of microbiology and epidemiology. He also spoke about improving graduate readiness for the transfer to infection control practice which requires a multifaceted approach that addresses factors affecting IPC knowledge and intentions both inside and outside the classroom. He also mentioned that there is a need for integration of these factors in our curriculum planning and design to enhance the competency of the graduates. Talk: Antimicrobial Stewardship 14:30 – 15:00 Hrs Dr. Sumanth Gandra, Infectious Disease Clinician, CDDEP spoke about the Antibiotic stewardship being selection, dosing, route and duration of antibiotic therapy. He also talked about the main reason why bacteria are becoming resistant to antibiotics and the main reason being overuse and misuse of antibiotics. He also spoke about why India has high antibiotic resistance prevalence as it the largest consumer of antibiotics after China. He also mentioned the goals of the antibiotic stewardship program which is to reduce consumption and inappropriate use of antibiotics, reverse adverse drug effects, reduce healthcare cost and decrease or limit the antibiotic resistance. He also said that it is difficult to implement anti biotic policy without proper infection control practices in place.
Antimicrobial Stewardship (Panel Discussion) 15:00 – 15:30 Hrs Panelists: • Dr. D Suresh Kumar, Consultant, Dept. of Infectious Disease & Tropical Medicine, Apollo Hospitals, Chennai • Dr. Samavedam Srinivas, Head, Dept. of Critical Care Medicine, Virinchi Hospitals, Hyderabad • Dr. Sumanth Gandra, Infectious Disease Clinician, CDDEP • Dr. Madhusudan R. Jaju, Consultant Critical Care Medicine, CARE Hospitals, Nampally, Hyderabad Moderator: Prof. Ramon Z Shaban, President, ACIPC, Australia Event Report Book 67
Health & ACCESS Conference Session Proceedings: Dr. Ramon Z Shaban started the panel discussion with putting forward the need to identify who uses the antibiotics and for what purpose. He also stated that the pharmacy departments in hospitals are fairly placed for starting the stewardship program. Dr. Sumanth Gandra stated that with respect to India the data regarding the use of antibiotics among demographics is not clear. He also mentioned that even though antibiotics are prescribed in the hospital, the tenant has to go, buy it and bring it back to the hospital. He talked about significant over the counter use of antibiotics. He also talked about the need for the education campaigns for the physicians also regarding the issue of antibiotic resistance. Dr. Samavedam Srinivas spoke about the problems in intensive control and self regulation. In Intensive control as the antibiotic dosing is talked about there is a knowledge gap thus there is a need for more robust system. The regulatory agencies need to have a tab on how many doses of particular antibiotic will dispense for a particular prescription, also check the minimum prescribed dose of the antibiotic and whether there had been an overshoot at the dispensing level. Dr. D Suresh Kumar talked about the Chennai declaration where all the medical agencies were called upon for their input regarding what should be done for the next five years. They also identified the key antibiotics that were brought under regulations which will not to be issued without prescriptions. The problem that the declaration is facing is that of the implementation and monitoring. He believes that there should be treatment guidelines that may help to control the antibiotic usage in the community. Dr. Madhusudan R. Jaju spoke about how there is a need to check the proper qualifications and training of the paramedical staff as well as the physicians so that there is sensitization at every level. He mentioned that they should also be made a stakeholder and accountable for the antibiotic resistance. According to him use of an antibiotic should begin with an end timeline kept in mind. He also spoke about how use of biomarkers and ancillary test will bring down the use of antibiotics.
Audience during Session
68
BioAsia2017
Health & ACCESS Conference Role of Healthcare Stakeholders for improved Infection Control Practices in hospitals (Panel Discussion) 15:30 – 16:15 Hrs
Panelists: • Dr. Guru N Reddy, Founder, Chairman and Managing Director, Continental Hospitals, Hyderabad • Dr. N. Krishna Reddy, Vice-Chairman, CARE Hospitals • Dr. GVS Murthy, Director, IIPH Hyderabad • Dr. Sunil K Khetarpal, COO & MS, Rajiv Gandhi Cancer Institute & Research, Delhi • Mr. Arvind Vasudeva, Promoter Director, Sanmed Healthcare Pvt Ltd Moderator: Mr. Vikas Dandekar, Chief Editor, CNBC TV18 Session Proceedings: Mr. Vikas Dandekar started the panel discussion by speaking about the problems regarding the antibiotics resistance and that there had not been many discoveries in this area. Mr. Arvind Vasudeva spoke about even though that there is a portfolio of antibiotics, a better way of working will be prevention and control of infections in hospital environment. The use of lower category antibiotic will help in prolonging and preventing use of antibiotic. He also talked about the initiatives of Drug Controller General of India of banning certain combinations and centralization of approvals because antibiotics are needed to be used very conservatively. Dr. Guru N Reddy spoke about the high infection rate in the intensive units and also that the infrastructure of the institute should be executed by incorporating and embracing appropriate guidelines. He also talked about the need to educate the Event Report Book 69
Health & ACCESS Conference doctors, paramedicals and the physicians by adopting a reward phenomenon rather than punishing on, recognizing why certain areas and disciplines are doing better than other specialties. He mentioned that to modify the behavioral patterns is to restrict access for the antibiotics prescriptions and also that there is a need for a robust public health system. Dr. N. Krishna Reddy spoke about the need for a prompt diagnosis of the infection. He stated that if it becomes mandatory from the providers to collect the data in terms of the surveillance of the disease patterns and antibiotic usage pattern across the country, it will be helpful in picking up the pattern for the resistance emerging even before it spreads to the community. Dr. Sunil K Khetarpal spoke about the role of each and every stakeholder as a caregiver. There is a need for hospitals to have infection prevention and control program and manual and an infection control committee. A close monitoring and deliberations and then corrective actions needs to be taken regarding these issues. He also talked about the importance of engineering controls in hospitals like the design of OT, OR and CSSD. Dr. GVS Murthy stated that there is a need for the segregation of three basic ways of dealing with prevention and control which are firstly the patient, community or population based initiatives, secondly the provider based initiatives, thirdly the health system per say. Each of these are major stakeholders and they have an important role to play. He also talked about the need to gather evidence for formulation and support of the policies.
Audience during Session
70
BioAsia2017
Satellite Events
Event Report Book 71
Satellite Events
BioAsia Connect BioAsia Connect is a dedicated B2B portal for online business partnering, event scheduling at BioAsia assisting the delegates in their development, research collaborations and licensing activities with the handpicked companies from the global life sciences market at the event. During 2 days of networking, in addition to commercial agreements and networking receptions, around 1200 trade and business partnership meetings were conducted this year at BioAsia enabling the participants to discuss new business prospects, evaluate company or investors profile and communicate directly with them regarding the potential collaborations and funding opportunities.
B2B Meetings during BioAsia 2017
72
BioAsia2017
Satellite Events
Pharmexcilâ&#x20AC;&#x2122;s International Buyer - Seller Meet Pharmexcil, with the support of Ministry of Commerce & Industry, Govt. of India, successfully hosted International Business Meet by inviting 25 Overseas Delegates from 10 Countries including regulatory officials and procurement agencies from various countries (Brazil, Colombia, Egypt, Ethiopia, Kazakhstan, Nigeria, Philippines, Sudan, Tanzania & USA). All together in the above meetings, 52 Indian delegates from 41 companies participated to establish their business relationship with global counterparts. It was noted that the meet successfully helped a lot of registered Indian companies to forge new business partnerships. During the meet, it was also established that in the Pharma sector, companies are required to obtain product registrations in the importing countries and that due to formal protocol; it will take some time to start the export of products as well.
Glimpses of Buyer-Seller meet Organised by:
Event Report Book 73
Satellite Events
BioAsia’s Think Bold Disrupting Healthcare Challenge With increasing pressure to reduce healthcare costs globally, emerging markets like India are gaining further prominence with key drivers like, Ageing Population, Rising Economy, Increasing Income Levels and Changing disease burden, especially towards lifestyle diseases & NCDs. Delivering affordable and quality health care to India’s billion-plus people presents enormous challenges and opportunities. Innovations could be a way out for a large number of people get quality care at a cost that the nation can afford. Doctors, Healthcare organizations and hospitals are increasingly feeling the pressure to get on outcomes and cost improvements quickly while delivering quality and accessible healthcare to patients and hence continually seek innovative healthcare delivery solutions. Under this context, BioAsia 2017 hosted a “Think Bold, Disrupting Healthcare Challenge” with a focus on Maternal & Child Health, Health IT, Eye Care, Emergency & Critical Care and Oncology, that attracted promising proposals and ideas from across the world with an objective to improve the innovation quotient of the healthcare ecosystem, providing the required thrust in Healthcare while giving a platform to connect with the industry executives, facilitators, mentors and domain experts who provided critical inputs on their products and services.
Key verticals of the Challenge:
Health IT
Eye Care
Oncology
Maternal & Child Health
Emergency & Critical Care
Partner:
Partner:
Partner:
Partner:
Partner:
Organizers:
In Partnership With:
shortlisted ideas
74
BioAsia2017
Challenge Supporters:
Satellite Events Following five ideas/startups were shortlisted by the jury for the final pitch to potential investors and experts.
ATS - Ambulance Tracking System
Bulls Eye
CardioTrak
Lattice Innovations
Onward Health
Mr. Ramesh Loganathan moderating the Healthcare Challenge Session
Healthcare Challenge Partners in conversation with the startups Event Report Book 75
Satellite Events
International Tradeshow With a special focus on Pharma Manufacturing, Innovation, Medical Devices & Diagnostics, Health IT and Digital Health, the International Tradeshow attracted around 100 companies and startups from across the globe. The exhibitor participation included Pavilion of Government of Telangana (which offered a Virtual Reality Experience of the Hyderabad Pharma City through a 360 degree simulated view), International Pavilion of the Illinois State (USA) hosting companies like Vetter Pharma, Exicure Inc., LanzaTech, Hospira, Aagami, Shamrock Structures, Akorn, Rosen Bioscience Strategies, etc., State Pavilions of Government of Rajasthan (Department of Science & Technology), Government of Uttar Pradesh (Council of Science & Technology) and Government of Assam (Guwahati Biotech Park), Corporate and MNCs like Novartis, GE Healthcare, MediTox (Czech republic), SysBiotech (France) etc., Alere Medical Pvt. Ltd., domestic companies like Dr. Reddyâ&#x20AC;&#x2122;s Laboratories, Aurobindo Pharma, Biological E. Limited, GVK Biosciences, Hetero Drugs Limited, Jubilant Biosys Ltd, MSN Laboratories, NATCO Pharma, Shantha Biotechnics Private Limited, Sanmed Healthcare Pvt. Ltd., IKP Knowledge Park, Shree Biocare, Kool-Ex Cold Chain Ltd., Jeevan Scientific Technology Ltd., Kriya Medical Technologies, iB Hubs, Keminntek Laboratories among others, Government and Academic organizations like Department of Biotechnology (Government of India), Biotechnology Industry Research Assistance Council (DBT-BIRAC), CSIRNational Chemical Laboratory Pune, CSIR-Central Scientific Instruments Organization, CSIR-Centre for DNA Fingerprinting and Diagnostics (CDFD), National Research Development Corporation, Osmania University (Biomedical Engineering Dept.), Indian Institute of Technology, Hyderabad (Centre for Healthcare Entrepreneurship), Public Health Foundation of India (PHFI), Hospital Groups like Care Hospitals, startups like Written Medicine , Viravecs Labs LLP, Edara Research Foundation (ERF), BiotechKart, PSPR 3D Tech (BITS Pilani), Theranosis Lifesciences Pvt Ltd, Call Ambulance, Nouvelle Biosolutions, among others. Around 400 visitors participated in the tradeshow airing the
Glimpses of BioAsia 2017 International Tradeshow
76
BioAsia2017
Satellite Events
Event Report Book 77
Satellite Events
Bio-Park Visit BioAsia 2017 featured an exclusive guided visit to the Genome Valley â&#x20AC;&#x201C; Indiaâ&#x20AC;&#x2122;s first systematically created life sciences cluster and the largest concentration of multi-tenated labspace infrastructure in an organized cluster. About 50 delegates visited the Genome Valley which entails tours to the Genome Valley Industries, innovation corridors, and premier institutions within the cluster like MN Park Synergy Square, Novartis, GSK, Ashland Campus, IKP Knowledge Park, etc.
Participants during the Bio-Park Visit
78
BioAsia2017
Satellite Events
India-Illinois Power Breakfast Meeting India-Illinois Power Breakfast Meeting was organized during BioAsia 2017, hosted by the Illinois Department of Commerce and Economic Opportunity, Office of Trade & Investment, Government of Illinois, USA. The objective of the meeting was to provide insights to the attendees into the range of biotech companies and university research activities in one of the most vibrant U.S. life science hubs and the cultural and business ties of this state and its major city, Chicago, to India. The meeting was well attended and represented by Illinois state companies like Rosen Bioscience Strategies, Lanza Tech, Vetter Pharma, Exicure, among others as well as Indian & Telangana based companies.
Hosted by:
India-Illinois Power Breakfast Meeting Session
Orphan Drugs Roundtable Meeting A high level roundtable on “Orphan Drugs - Discovery and Development” was organized on February 7th during BioAsia 2017 in Hyderabad, under the Chairmanship of Prof. Ramaiah Muthyala, Associate Director, Center for Orphan Drug Development, University of Minnesota and President/CEO, Indian Organization for Rare Diseases. and under the Co-Chairmanship of Dr. G. Narahari Sastry, J C Bose National Fellow, Molecular Modeling Group, CSIR- Indian Institute of Chemical Technology, Hyderabad. The meeting was well attended and included representatives from CSIR-Indian Institute of Chemical Technology, Dr. Reddy’s Institute of Lifesciences, iB Hubs, Divi’s Laboratories, Osmania Mecial College, CSIR – Centre for Cellular & Molecular Biology among others.
Event Report Book 79
Satellite Events
BioAsia Launch Pad •• The Government of Telangana signed an MoU with Cerestra to explore a lifesciences infrastructure fund to the tune of INR 1000 Crores to create a modular plug-and-play infrastructure for pharma/biotech/medical devices industry •• A cumulative investment announcement of over INR 3000 Crores was also made for creation of specialized infrastructure for life sciences industry which will mark the beginning of the next wave of development in the State and will be termed as Genome Valley 2.0.
Signing of MoU between Government of Telangana and Cerestra
hh A number of Initiatives were launched during BioAsia 2017 with investments to the tune of INR 1700 Crores. hh New SEZ facility of Biological-E for the manufacturing and research for increasing their vaccine product pipeline was launched. The event also had announcements of MN Park Phase 2 ready to occupy laboratory space of about 2 million sq feet, 50000 sq feet of ICICI Knowledge Park catalyst and most importantly 3-D model of the country’s largest animal resource facility of Government of India being developed in the partnership with Government of Telangana was announced.
•• The event witnessed land allotment of letters to 6 companies with the cumulative investment of INR 672 Crores
Land Allotment Letters Ceremony
Signing of MoU between Novartis and NIPER
•• Novartis signed an MoU with National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, during BioAsia 2017 towards building capabilities and skills. •• The event also saw the unveiling of TB Free Telangana initiative of Government of Telangana in partnership with J&J - Flagging off the autos and buses with awareness messages on TB
80
BioAsia2017
Flagging off the autos and buses with TB awareness messages
Media coverage
Event Report Book 81
Media Coverage
Highlights - BioAsia 2017 Media Coverage
Print Coverage Snapshot Print Coverage clips in print - 209
Total coverage clips Online - 153
Number of Cities covered - 11
English Coverage – 146 Vernacular Coverage – 63
BioAsia mention in Headline 77 Clips
No. of Pictures in clips - 144
Overall coverage categories:
82
BioAsia2017
Media Coverage
Pan India Visibility - Cities 11
Coverage Spread â&#x20AC;&#x201C; Pre event and during the event
English Vs Vernacular Print Media Coverage
Pre event - 169
Event / Post Event - 193
Event Report Book 83
Highlights - BioAsia 2017 Media Coverage
84
BioAsia2017
FEEDBACK & COMMENTS
Event Report Book 85
FEEDBACK & COMMENTS
“It was a great honor to be recognized with the Genome Valley Excellence Award during the 2017 BioAsia conference, and to join the ranks of other esteemed researchers and innovators who have received this prestigious recognition. I hope that my remarks were well-received by the participants. I thoroughly enjoyed the conference, and I commend you and your team for putting together an outstanding program. I wish many future successes with the BioAsia conference and beyond.” Dr. Paul Stoffels
Worldwide Chairman of Pharma, Chief Scientific Officer, Johnson & Johnson, USA
“I extend my heartfelt thanks to you for a fruitful meeting and my congratulations to your team for a well-organized BioAsia 2017 meeting.” Dr. Vas Narasimhan
Global Head of Drug Development & CMO, Novartis, Switzerland
“The quality and diversity of topics showcased at BioAsia was very impressive. It created a platform to share perspectives and reflect on the challenges and opportunities for the life sciences sector in Asia as part of a global science community. Looking to the future it is clear that innovation and collaboration are key to delivering new medicines that meet the needs of patients.” Dr. Patrick Vallance President R&D, GSK
86
BioAsia2017
“I must say that this is one of the best conferences in the pharmaceutical industry in India. It is well organized and insightful. I am glad to see cooperation between the manufacturers, government and the pharma community on one single platform. Once again congratulations on organizing an excellent conference and I am looking forward to this event in the next year.” Mr. Glenn Saldanha
Chairman and Managing Director, Glenmark Pharmaceuticals, India
“BioAsia 2017 was an outstanding conference. The presentations made by the keynote speakers and the panel discussions sharing experiences and the future of science were truly fascinating. The succinct slides gave us a close look at the research being carried out for the many unmet medical needs and hope to the millions of families impacted by these diseases. Thank you so much for organizing this conference as well as sharing of time and experiences with so many erudite speakers.” Mr. Ranjit Shahani
Vice Chairman & Managing Director Novartis India Limited
FEEDBACK & COMMENTS
“I was impressed with the agenda, content and speakers at BioAsia 2017. The agenda was well thought through and equally well curated. There were outstanding speakers delivering valuable content and clear messages. I found BioAsia 2017 interesting and impressive”
“I want to thank you for the support provided during my participation in BioAsia. I was positively impressed by the high caliber of BioAsia 2017, especially about the morning session of lectures on February 7.” Nobel Laureate Prof. Kurt Wuthrich
Mr. BVR Mohan Reddy
Scripps Research Institute USA
Executive Chairman, Cyient, Chairman Board of Governors, IIT Hyderabad & Honorary Consul for Germany (Telangana and Andhra Pradesh)
“BioAsia 2017 was a wonderful experience. The topics and speakers were in-tune to the theme of the conference. Participation in the Laboratory Automation session was a mode to exchange the novel scientific ideas and projects in automation. The greatest achievement was the active participation by the delegates who were both from the medical as well as non-medical fraternity. Concrete proposals and plans for the continual improvement in the diagnostic laboratory was a welcome step during the conference. We hope such lively session would be beneficial to all and we often get to experience such discussions in the upcoming conferences.” Dr. Animesh Bardoloi
“It was a fantastic and a unique experience at BioAsia 2017. Listening to the bosses of big corporate houses, the CEOs and their journey to what they have achieved, was very interesting and inspiring. Also I could look from a different angle about the opportunities which our people could explore and we were not much aware of. Interaction with the Noble Laureate was amazing. Keep it up and we look forward to more of such gatherings.” Dr. Jasbinder Kaur
Department of Biochemistry, Government Medical College & Hospital, Chandigarh
Head of Laboratory Services Department of Laboratory Medicine Narayana Hrudayalaya , Guwahati
“It was amazing to meet the best brains in the Industry and discuss topics relevant to the Industry. I learnt a lot through my interactions with fellow participants and I can tell Life Sciences is going to be the next Bastion of Indian professionals after IT. It was also a great platform to establish Mentor-mentee relationships that will benefit the Industry and academics in longer run.” Mr. Anubhav Asthana
Managing Director – Consulting Deloitte India
Event Report Book 87
FEEDBACK & COMMENTS
“BioAsia 2017 had been very diligently planned and professionally organised in every sphere of its hosting. All delegates who participated in the event have immensely benefited in terms of emerging opportunities, breakthrough bio technologies and potential business value adds in Bio Pharma space. Cross knowledge sharing across the boundaries and network partnership provided to the delegates was absolutely fantastic. Delegates both from India and abroad have also explored potential synergy between biopharma and synthetic pharma spaces towards greater co-existence.” Mr. M. Madan Mohan Reddy Director, Aurobindo Pharma Ltd.
“The challenge in the Indian healthcare sector is improving the quality of patients’ lives by constantly driving innovation and access. India is in a sweet spot well poised to deliver, given that we are a global technology giant with a large pool of highly qualified scientific talent. BioAsia 2017 was a great forum that brought together leaders in healthcare and technology to explore ideas for the future of healthcare.” Mr. A. Vaidheesh
Managing Director, GSK Pharmaceuticals Ltd & VP – South Asia
“I believe BioAsia was the best event in many years. It has set a new standard and I am sure it will draw the best attention from global speakers in the future. Congratulations to the very hardworking team to have accomplished this feat.” Mr. Vikas Dandekar Chief Editor - News CNBC TV18
“BioAsia is a powerful catalyser of ideas and also a great place to meet people and forge collaborations. It has been a great supporter of Healthcare Innovation and has actively encouraged young talent in this domain. Great to see incremental progress year after year!” Dr. Anthony Vipin Das LV Prasad Eye Institute, Hyderabad
88
BioAsia2017
“It was a pleasure to be a part of BioAsia 2017, and I look forward to participating again. I was impressed with the event’s organization, and also the level of participation and Q&A during my panel on “Disruptive Innovation”. The conference is a good platform for leaders from the government and industry to connect, as well as share their thoughts with a diverse audience. It is also a great event to highlight the innovation happening in healthcare in the state of Telangana”. Mr. Kaustubh Bhatnagar
Business Lead, Shruti – Innovation Programme, Medtronic India
Organizers:
In Partnership With:
Supported By:
BioAsia Secretariat: #301, Gayathri Nest, Telecom Nagar, Gachibowli Hyderabad - 500032, Telangana, India. T: +91 (40) 2300 0205 / 206 E: info@bioasia.in, www.bioasia.in
Knowledge Partner: